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Abstract 
 
Apoptosis, also known as programmed cell death, is a very critical process for the 
maintenance of tissue homeostasis in multicellular organisms.  In our immune system, which 
is comprised of different cell types with different but interconnected functions, apoptosis 
plays a crucial role in preserving homeostasis during development, throughout adult life and 
upon termination of immune responses.  Any defects in apoptosis can potentially lead to 
autoimmunity or cancer. 
 
CD95 (Fas/APO-1) belongs to the family of the so-called death receptors, and upon binding 
with its ligand, the CD95L, can instruct CD95-bearing cells to undergo apoptosis.  The 
CD95/CD95L system is crucial for homeostasis of the immune system, and deregulation of 
CD95-mediated apoptosis results in several diseases including autoimmune syndromes, 
leukaemias or AIDS. 
 
CD95-mediated apoptosis is used by the T-lymphocytes of the immune system at several 
stages during their development and after the termination of an immune response, so that the 
quality and quantity of activated T cells are controlled.  In these cases, the T cells being 
activated through their TCR die via CD95-mediated apoptosis upon restimulation, a process 
collectively known as activation-induced cell death (AICD). 
 
One characteristic of cancer is its resistance to apoptosis.  Leukaemias are no exception.  One 
of the ways a cancerous T-lymphocyte evades death is by deregulating its CD95/CD95L 
system by e.g., downregulating the CD95L.  NF-AT and Egr proteins (1-3) are amongst the 
different transcription factors that take part in the regulation of the CD95L.  Upon TCR 
stimulation different signalling pathways lead to the activation of NF-AT and the 
transcriptional activation of Egr factors.  These then bind on the CD95L promoter and activate 
it.   
 
Wilms’ tumor gene 1 (WT1) encodes a four-zinc-finger protein. Alternative splicing at the 
pre-mRNA level yields several transcript variants, of which the best characterized are the so 
called WT1-KTS and WT1+KTS isoforms. The WT1-KTS isoform, which lacks three amino 
acids between zinc-fingers three and four, is suggested to be a transcription factor that belongs 
to the Egr family and has target sequences similar to Egr1.   
 ii
WT1 is expressed during the early stages of haematopoiesis and has been implicated in 
leukaemogenesis.  Its role in leukaemias is controversial as it is either found to be mutated or 
overexpressed, and overexpression is linked with more immature leukaemias.  It is therefore 
uncertain whether WT1 is a tumor suppressor or tumor promoter.   
 
In this study the expression of WT1 is analyzed in eight leukaemic T-cell lines (Jurkat 16, 
Jurkat 282, CEM, Myla, Hut78, SeAx, Molt4 and HH) and in primary T cells. It is shown that 
WT1 is not expressed in mature T cells.  Also, contrary to previous reports that support 
overexpression of WT1 in Jurkat and Molt4, no expression of WT1 is seen in these cell lines 
in this study.  Expression of WT1 is detected in only two of the leukaemic cell lines (CEM 
and Hut78).  In the latter, no mutations are detected in WT1.  The expression of WT1 
coincides with CD95L expression and high AICD in these cell lines.   
 
Moreover, ectopic expression of WT1-KTS in a WT1-non-expressing cell line upregulates the 
CD95L and enhances AICD.  Silencing of WT1-KTS in a WT1-expressing cell-line reduces 
CD95L transcription and dramatically decreases the levels of AICD.  Examination of three 
putative WT1 binding sites on the CD95L promoter (Egr sites) indicates that WT1-KTS acts 
through the CD95L promoter Egr sites.  Mutations of these sites completely abolish the effect 
of WT1-KTS.  Furthermore, a detailed analysis of individual binding sites and electrophoretic 
mobility shift assays reveal that WT-KTS can directly bind on the CD95L promoter at 
position -120, relative to the transcription start site (+1). 
 
Taken together, the results of this piece of work disagree with previous reports on the 
overexpression status of WT1 in the leukaemic T cell lines Jurkat and Molt4.  Expression of 
full-length WT1 is only supported for the cell lines CEM and Hut78.  In agreement with 
previous work, WT1 is not expressed in healthy mature T cells.  This work also supports the 
transcription factor function of WT1-KTS, as it can regulate CD95L transcription.  Finally, it 
shows for the first time the ability of WT1-KTS to bind on the CD95L promoter and 
upregulate the CD95L upon T cell activation in leukaemic T-cell lines. 
 
The correlation for the need of WT1 during haematopoiesis, its loss in leukaemias and its 
ability to cause CD95L-mediated apoptosis in the leukaemic cell lines that express it, support 
a possible function for WT1 as a tumor suppressor in the course of leukaemogenesis.   
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I Introduction  
 
 
1. Apoptosis - Programmed cell death 
 
 
During development and in adult life a vast number of cells are known to die in many 
different tissues in both vertebrates and invertebrates.  Naturally occurring cell death has been 
investigated since the nineteenth century, highlighting its importance and until nowadays a 
significant research effort has been directed towards unravelling the role of cell death, the 
signals that regulate it, and the mechanisms by which cell destruction is actually achieved.  
Although cell death was probably already considered by Aristotle for the regression of the 
ductus arteriosus after birth (Barclay et al, 1944), it was not until 1842, when the ‘cell theory’ 
was established (Schwann, 1839) and cells could be visualized under a microscope, that Vogt 
could actually detect the disappearance of cells while he was studying the development of the 
midwife toad (Alytes obstetricians) (Vogt, 1842).  Gradually, evidence for the existence of 
naturally occurring cell death accumulated (Clarke & Clarke, 1996), and it was subsequently 
realized that there is not only one way a cell can die (Lockshin & Williams, 1965).  The roots 
of the morphological distinctions between different cell death types go back to 1972 when the 
term ‘apoptosis’ was also introduced (Kerr et al, 1972).  It is now known that the cell death 
that Vogt saw is what is called ‘programmed cell death’ or apoptosis and along with necrosis, 
they comprise the best characterized ways of cell death.  Interestingly enough, there is no 
precise definition for either process and distinction between the two types is based on 
morphological features and the cause of death.  
 
Necrosis is generally considered as a passive process and takes place upon physical or 
chemical injury such as oxygen deprivation in the heart muscle during a heart attack (Roeske 
et al, 1977).  In necrosis, the damaged cell enlarges with consequent plasma membrane 
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disruption, followed by the release of cytosolic components in the extracellular space, an 
event that causes inflammation (Proskuryakov et al, 2003).  Contrary to necrosis, apoptosis is 
thought to be an active genetically encoded process. The apoptotic process is initiated by 
several stimuli including growth factor deprivation, UV- or γ- irradiation (Kasibhatla et al, 
1998), chemotherapeutic agents (Friesen et al, 1999; Eichhorst et al, 2000) and a family of 
transmembrane proteins the so called ‘death receptors’ upon engagement with their 
appropriate ligand (Li-Weber & Krammer, 2003).  After initiation, an executionary phase 
follows during which the apoptotic cell shrinks, the plasma membrane inverts exposing 
phosphatidylserine, blebbing (zeiosis) occurs, the nucleus is fragmented, chromatin condenses 
and eventually endonucleases produced by the dying cell cleave the DNA between 
nucleosomes (Garcia-Martinez et al, 1993; Nagata et al, 2003). In this way the DNA is 
fragmented into 200 bp pieces, which upon electrophoresis produce the characteristic ‘DNA 
ladder’ found in  apoptotic cells (Wyllie et al, 1980; Montague & Cidlowski, 1996).  Finally, 
the apoptotic process is terminated by the appearance of ‘apoptotic bodies’, which are 
membrane-enclosed vesicles containing the remainders of the cell and are engulfed by 
phagocytic cells, hence preventing inflammation (Krammer, 1999).  Apoptosis is crucial for 
tissue homeostasis and remodelling during development, in the nervous system and in the 
immune system (Krammer, 1999; Vaux & Korsmeyer, 1999; Arnold et al, 2006) 
 
2. T-lymphocyte apoptosis and activation-induced cell death (AICD) 
 
2.1 T-lymphocytes 
The human immune system is a community that consists of different cell types, namely T- 
and B- lymphocytes, natural killer (NK) cells, macrophages, antigen-presenting cells (APCs) 
and their various subclasses, which have to work together, interact and communicate with one 
another in order for the system to function properly and the organism to remain healthy.  The 
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T-lymphocytes (T cells) develop in the bone marrow from haematopoietic stem cells into 
immature T cells.  They then emigrate from the bone marrow into the thymus, where they 
mature and are positively or negatively selected, depending on the affinity of their T-cell 
antigen receptors (TCR) for self major histocompatibility complex (MHC) antigens class I 
and II (Sebzda et al, 1999).  The TCR is a multiprotein complex made up of clonally variable 
antigen-binding chains (heavy TCRα and light TCRβ immunoglobulin chains) that are 
associated with invariant accessory proteins, which are collectively called CD3 (Call & 
Wucherpfennig, 2005).  Signaling from the TCR requires not only the presence of CD3 but 
also the help of a co-receptor namely CD4 or CD8.  T cells that interact with MHC class II 
molecules develop into T cells that express CD4 on their surface (CD4+) and T cells that have 
high affinity for MHC class I express CD8 on their surface (CD8+) (Basson & Zamoyska, 
2000; Basson & Zamoyska, 2001).  Only the mature T cells that have a functional TCR are 
allowed to leave the thymus and home secondary lymphoid organs such as the spleen and 
lymph nodes.  Mature CD4+ T cells function as helper T cells, and by secreting cytokines they 
can either regulate cellular immune responses [T helper1 (Th1) cells] or antibody responses 
[T helper 2 (Th2) cells] (Jankovic et al, 2001).  Mature CD8+ T cells function as cytotoxic 
effector cells (T effector/T killer) (Sebzda et al, 1999).   
 
When the organism is threatened by an infectious agent, APCs present antigen-specific 
peptides from the infectious agent under inspection to the T cells (Drakesmith et al, 2000).  
Communication between APCs and T cells through antigen-MHC complexes, co-stimulatory 
cell-surface molecules and cytokine production, activates T cells.  Activated T cells then 
proliferate by clonal expansion, and in their own turn contact other T cells (T killer cells) or B 
cells to instruct them so that the infectious agent is quickly and effectively eliminated with as 
few casualties as possible. 
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 2.2 T-lymphocyte death 
Death of T cells occurs via apoptosis and is destined to control the quality of the T cells so as 
to prevent autoreactive events that could lead to autoimmunity.  In addition, apoptosis 
functions to control the quantity of the T cells especially after an immune response so that 
homeostasis is maintained and both autoimmunity and leukaemias are prevented.  After 
having entered the thymus, immature T cells undergo rearrangement of their TCR genes in 
favour of their differentiation.  Successful TCR rearrangement leads to further maturation and 
TCR-affinity based positive and negative selection of the T cells (Surh & Sprent, 1994).  
Failure of proper TCR rearrangement leads to the inability of stimulation by self-MHC-
peptide complexes and these T cells die by neglect.  Only T cells that express a TCR that can 
interact with self-MHC are positively selected and rescued (Marrack & Kappler, 1997).   T 
cells that express self-reactive antigen receptors that bind to self-MHC peptide complexes 
with high affinity are negatively selected and are eliminated by apoptosis (Nossal, 1994). 
These check points during T-lymphocyte development ensure that self-MHC restriction and 
self-tolerance are successfully accomplished before the T cells finally get to the periphery 
(Kishimoto & Sprent, 2000a; Kishimoto & Sprent, 2000b).  Therefore, only 2-4% of the T 
cells that develop in the thymus will finally leave the thymus as mature T cells (Chen et al, 
1983).  In the periphery, if a T cell can not be efficiently stimulated by growth signals it also 
dies by neglect (Nelson & Willerford, 1998).   
 
 2.3 Activation-induced cell death  
In the periphery, upon infection, resting mature T cells are activated by antigens via their TCR 
and the adaptive immune response is initiated.  In order for the immune effect to be 
augmented activated T cells undergo clonal expansion and their numbers increase 
dramatically.  However, after the clearance of infection, such high numbers are not needed 
any more and activated T cells die by apoptosis.  Only a small fraction of antigen-specific T 
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cells survive as long lived memory T cells (Sprent & Surh, 2002).  This results in a drop in the 
numbers of activated T cells so that homeostasis is maintained (Fig.I.1).    
 
Figure I.1.  Graph showing the course of a T cell immune response and the apoptosis 
phenotype for each phase (Krammer, 1999).   
 
 
 
 
 
 
 
 
There are currently two mechanisms by which apoptosis of pre-activated T cells takes place in 
the periphery.  One is ‘activated T cell autonomous death’ (ACAD) caused by cytokine 
withdrawal (Lenardo et al, 1999; Hildeman et al, 2002).  The other one is called activation 
induced cell death (AICD) (Shi et al, 1989) and has the special characteristic that it requires 
the involvement of TCR-stimulation induced pathways of death receptors and death ligands.   
The death receptors belong to the tumor necrosis factor (TNF)/nerve growth factor (NGF) 
receptor superfamily.  They are type I transmembrane receptors, characterized by the presence 
of two to five cysteine-rich extracellular repeats that are important for ligand binding 
(Orlinick et al, 1997a & 1997b) and an intracellular 80 amino-acid long death domain (DD), 
which is necessary for the transduction of the apoptotic signal (Itoh & Nagata, 1993).   
 
The receptors recognized so far include TNF-R1 (CD120a), CD95 (APO-1/Fas), DR3 (APO-
3, LARD, TRAMP, WSL1), TNF-related apoptosis-inducing ligand (TRAIL)-R1 (APO-2, 
DR4), TRAIL-R2 (DR5, KILLER, TRICK2), and DR6 (Schulze-Osthoff et al, 1998).  The 
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Ectodysplasin A receptor (EDAR) and the nerve growth factor receptor (NGFR) are also 
sometimes referred to as death receptors (French & Tschopp, 2003; Wajant, 2003).  Death 
receptors are activated by their ligands that have co-evolved as a death ligand family. Among 
the death receptors, the best characterized system for AICD induction is the CD95 and its 
ligand the CD95Ligand (CD95L) (Dhein et al, 1995; Ju et al, 1995; Alderson et al, 1995). 
 
 
3. The CD95/CD95L system  
 
3.1 CD95/CD95L in apoptosis signalling  
The apoptosis pathway via the CD95 system is initiated when CD95 binds to its ligand.  This 
can occur in an autocrine manner, where the cell produces its own CD95L which can then 
bind to CD95 located on the same cell’s surface leading to the cell committing suicide. 
Another possibility is that it can take place in a fratricide/paracrine fashion, where one cell 
produces CD95L that binds to the CD95 on a neighbouring cell’s surface and hence instructs 
that cell to die (fratricide)  (Krammer, 2000) (Fig.I.2).   
 
Figure I.2. Schematic diagram showing the different modes of AICD 
Upon TCR stimulation with antigen-specific MHC complex, the CD95-bearing T cell gets 
activated and produces CD95L.  CD95L can either bind on CD95 of a neighbouring T cell 
passing on the death signal (1), or it can be recognized by self-receptor leading to the suicide 
death of the T cell (2), or it can be passed on a CD95-bearing cell further away and cause 
activation of the death pathway (3). 
 
CD95+ cell
CD95
 
 
 
 
 
 
 
↑CD95L
MHC + 
Antigen
TCR
321
fratricide CD95suicide paracrine
CD95
CD95+ T cell Activated T cell
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In any case, binding of CD95L to CD95 triggers the formation of the death-inducing 
signalling complex (DISC) (Kischkel et al, 1995), from which the apoptotic signals emanate 
(Fig.I.3). The exact stoichiometry of the DISC is not fully understood but the protein 
interactions that take place through homotypic protein domains are well characterized.  The 
CD95 DISC is composed of oligomerized, most probably trimerized CD95, which through its 
DD recruits the serine phosphorylated adapter Fas-associated DD (FADD)/Mort1 (Chinnaiyan 
et al, 1996).  FADD, which also has a death-effector domain (DED), in turn reacts with the 
DED of two isoforms of caspase-8 [caspase-8/a (FADD-like interkeukin-1β (IL-1β)-
converting enzyme (FLICE, Mach-α1) and caspase-8/b (Mach-α2)] (Muzio et al, 1996; 
Boldin et al, 1996; Golks et al, 2006), caspase 10 (Sprick et al, 2002) and c-FLIPL/S/R (Thome 
& Tschopp, 2001; Golks et al, 2005).  
 
Caspases are aspartate-specific cysteine proteases that are produced in a pro-enzyme 
(zymogene) form, which release active enzyme after proteolytic cleavage.  As such, binding 
of caspase-8 and -10 to FADD leads to their activation by autoproteolysis (Martin et al, 
1998).  The active caspase works as a heterotetramer containing two large subunits with the 
active site (catalytic domain) and two small subunits (prodomain) (Earnshaw et al, 1999).  
After activation of caspase-8, the prodomain remains at the DISC and the active caspase-8 
heterotetramer p102-p182 dissociates from the DISC to initiate a cascade of activation of other 
caspases, an event that marks the executionary phase of apoptosis (Lavrik et al, 2003; Golks 
et al, 2006).  
 
Two different pathways for CD95-mediated apoptosis have been described, the 
mitochondrial-dependent and mitochondrial–independent pathways, corresponding to the 
quantity of DISC formation and caspase-8 activation. Accordingly, the cells can be 
categorized by the pathway they follow in type I (mitochondrial-independent) and type II 
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(mitochondrial-dependent) cells (Scaffidi et al, 1998).  In type I cells, high amounts of active 
caspase-8 are produced at the DISC, which can process the effector caspase-3. Active 
caspase-3 in turn activates caspases -6 and -7, whose activation is responsible for the cleavage 
of several cellular substrates.  This finally leads to morphological changes of the cell and to 
DNA fragmentation.  In type II cells, DISC formation is low and as a result little active 
caspase-8 is produced.  In these cells apoptosis induction depends on the activation of the pro-
apoptotic molecule BID, which is a Bcl-2 homology domain-3 (BH3) containing Bcl-2 family 
member (Luo et al, 1998).  When BID is activated by cleavage, the active form, tBID (‘t’ for 
truncated) is produced, which migrates to the mitochondria, where it sequesters and co-
operates with Bax and Bak proteins.  This protein aggregation is thought to result in the loss 
of the mitochondrial membrane potential (ΔΨm) and the release of pro-apoptotic molecules 
like cytochrome c (Korsmeyer et al, 2000).  Cytochrome c associates with the apoptotic 
protease-activating factor-1 (Apaf-1), deoxyadenosine triphosphate and caspase-9 forming a 
large protein complex, the apoptosome (Li et al, 1997).  The apoptosome can then activate 
caspase-9, which in turn activates caspase-3 and -7 and finally apoptosis via the mitochondrial 
pathway can be brought to completion.   
 
T cells that are not activated or memory T cells are resistant to apoptosis and behave like type 
II cells, forming CD95 DISC in smaller amounts.  In type II cells apoptosis can be blocked at 
the DISC level via cellular FLICE inhibitory protein (c-FLIPL/S/R) (Schmitz et al, 2004) and 
also at the mitochondrial level by upregulation of the anti-apoptotic Bcl-2 family members; 
Bcl-2 and Bcl-xL (Peter et al, 1997).  T cells which are sensitive towards apoptosis, like the T 
cells at the termination of an immune response, behave like type I cells, since they form a lot 
of CD95 DISC complexes which can activate a strong caspase cascade independent of the 
mitochondria.  Therefore, it has been suggested that T cells after activation switch from 
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apoptosis resistant type II phenotype to apoptosis sensitive type I phenotype (Krueger et al, 
2003).   
Figure I.3.  Signalling pathways induced by CD95.  CD95 signalling pathway (including 
DISC formation) used in type I and type II cells. DISC formation leads to caspase-8 
activation.  In type I cells the extrinsic apoptosis pathway is followed (shown in yellow). 
Active caspase-8 directly cleaves caspase-3, which in turn activates other effector caspases.  
The effector caspases-6 and -7 along with caspase-3 cleave other protein targets an event that 
finally leads to death.  In type II cells (shown in light green) the intrinsic apoptosis pathway is 
followed where the cascade is amplified through the mitochondria.  Truncated Bid (tBid) 
mediates cytochrome c release from the mitochondria leading to the formation of the 
apoptosome, in which caspase-9 is activated.  Active caspase-9 in turn activates caspase-3 and 
other effector caspases, finally causing death.  The caspase activation is inhibited at the DISC 
level by c-FLIP proteins, at the cytoplasmic level by IAPs and at the mitochondrial level by 
Bcl-2 proteins.   
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3.2 CD95/CD95L in disease  
The CD jor role in apoptosis induction and more particularly in 
 humans, CD95 and CD95L mutations are found in autoimmune lymphoproliferative 
kill neighbouring CD95-bearing cells.  
95/CD95L system plays a ma
AICD of T cells.  Any malfunctions in this system can prove to be detrimental for the fate of 
T cells and subsequently for the organism.  This is best understood when describing the 
phenotype of lpr (for lymphoproliferation) mice that lack a functional CD95, as well as gld 
(for generalized lymphoproliferative disease) mice that bear a mutant CD95L, which exhibit 
various autoimmune phenomena resembling systemic lupus erythematosus in humans. Both 
mouse strains produce autoantibodies and accumulate abnormal CD4- CD8- T cells leading to 
lymphadenopathy, splenomegaly, and other autoimmune symptoms (Cohen & Eisenberg, 
1991; Nagata & Suda, 1995).   
 
In
syndrome (ALPS) patients.  ALPS type Ia patients carry mostly heterozygous dominant 
negative mutations in CD95 and ALPs type Ib patients have mutations in CD95L.  These 
patients display lymphadenopathy and splenomegaly due to impaired apoptosis (Rieux-Laucat 
et al, 1995; Fisher et al, 1995).  Deregulated expression of CD95 and CD95L is also linked 
with systemic lupus erythematosus (SLE) (Kovacs et al, 1997) and CD95L has been shown to 
be mutated in a patient with SLE (Wu et al, 1996).  In addition, the involvement of CD95 and 
its ligand in AIDS has been hypothesized, as the levels of CD95 and CD95L have been shown 
to correlate with disease stage (Bahr et al, 1997; Bohler et al, 1997).  Also, the HIV protein 
TAT was recently shown to induce CD95L expression and might play a role in T cell loss 
during AIDS disease progression (Li-Weber et al, 2000; Gulow et al, 2005).  Except for 
CD95 itself, another equally important player in the system is inevitably its ligand, as when 
there is CD95L there is no initiation for apoptotic signalling in AICD.  Therefore, the ability 
of a T cell to express CD95L determines its ability to commit suicide upon AICD and/or to 
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4. The CD95L and its transcriptional regulation 
 
CD95L is a 40kDa glycoprotein with a cytosolic N-terminus and an extracellularly oriented 
-terminus.  Membrane-bound CD95L can be cleaved by metalloproteases producing a 
rized in Fig.I.4 and it 
an be pointed out, that chemotherapeutic drugs, oxidative stress and UV or γ- irradiation can 
C
soluble form of CD95L (Mariani et al, 1995) but the functional differences between the two 
forms are not very well characterized (Fig.I.2).  Although CD95 is widely expressed, CD95L 
expression is very restricted.  It is expressed on activated T cells (Suda et al, 1995), NK cells 
(Oshimi et al, 1996), at immune-privileged sites of the corneal epithelium and the retina of the 
eye (Griffith et al, 1995), on Sertoli cells of the testis (Bellgrau et al, 1995) and on certain 
tumors (Hahne et al, 1996; O’Connell et al, 1999).  It is important for AICD of mature T cells 
and it is also suggested that it is involved in the apoptosis of T cells during their development 
in the thymus (Ogasawara et al, 1995; Castro et al, 1996; Fisher et al, 1996). Deregulation in 
CD95L expression can be detrimental and constitutive expression has been linked with 
lymphoproliferative disorders in animal studies (Watanabe et al, 1995) 
 
The pathway from the TCR that leads to CD95L upregulation is summa
c
also cause CD95L upregulation.  Depending on the stimulus, different or sometimes 
overlapping pathways are followed that lead to the activation/transcriptional 
activation/assembly of specific transcription factors, which can eventually bind on their target 
sequences on the promoter of CD95L and hence activate its expression.  Transcriptional 
activation of the CD95L gene in T cells occurs rapidly.  CD95L mRNA can be detected as 
early as 1h following anti-CD3/anti-CD28 or phorbol myristate acetate (PMA)/ionomycin 
stimulation and reaches a maximum after 4h (Li-Weber et al, 2002). The CD95L promoter 
spans 960 bp and regulatory factors have been shown to bind from -860 to +100 relative to 
the transcription start site (+1) (Table I.1) (Li-Weber & Krammer, 2003). 
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Figure I.4. Main signalling pathways leading to CD95L upregulation.  Schematic 
representation of the different stimuli and the pathways they stimulate for CD95L mRNA 
production.  Each signalling cascade results in the production of active transcription factors 
targeting the CD95L promoter.  Signals from the TCR, activate NF-AT and NF-κB 
transcription factors and in turn NF-AT upregulates Egr, which can bind on the CD95L 
promoter.  TCR signalling also goes through the Ras pathway, which produces Jun/Fos 
dimers (AP-1).  Cancer drug treatment, PMA, UV and Hydrogen peroxide affect NF-κB 
production and UV/stress can also act through MEK for AP-1 production. 
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Table I.1.  Transcription factors (TF) and their target sequences on the human CD95L promoter in T cells 
        
ne of the major interactions that take place on the CD95L promoter is mediated by the 
uclear factor of activated T cells (NF-AT) and early growth response (Egr1-4) proteins.  
 
 
  
 CD95L promoter      TF                             Binding sites                                Reference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
n
Three binding sites for NF-AT have been identified on the CD95L promoter at positions -120, 
-180 and -680 relative to transcription start site (+1) (Latinis et al 1997; Holtz-Heppelmann et 
al, 1998; Li-Weber et al, 1998).  Also, it has been shown that both -120 and -180 are 
composite Egr/NF-AT binding sites where both NF-AT and Egr1/2/3 proteins can bind (Li-
+1 
-980 
-680 
-530 
-230 
-180 
-120 
-50 
-65 
-30 
+65 
+90 Eichhorst et al, 2000 
 
Kirchhoff et al, 2002 
 
Latinis et al, 1997 
Li-Weber  al, 2000 
Kirchhoff  al, 2002 
Mittelstadt & As
Li- 9 
Holtz-Heppelm  et al, 1998 
Li-Weber  al, 1999 
Li-Weber  al, 1999 
Kasibhatla , 1999 
AP-1 (Jun/Fos) 
 
IRF-1/vIRFs 
 
CCTGACTCACC 
 
 
 
 
 
GAGAAGAAGTAAACCGTTTG 
 
  
  
  
    TATA box 
c-Myc T  GGAAACTCTATAAGAGAGATCC
NF-AT TGGAAACTCTATAAGAGAGATCC 
  
NF-κB/SP-1 
IRF-1/vI Fs 
 
 
Egr/SP-
GAGGTGTTTCCCTT 
R AGAGAAAGAG AGACAGAGG AA
  
 
 
1 GCTGCAAAGTGAG GGGTGTTTCTTTG T
NF-AT GCTGCA TCTTTG AAGTGAGTGGGTGTT
IRF-1/vIRFs GCT TG GCAAAGTGAGTGGGTGTTTCTT
  
NF-AT 
Egr/SP-
 
ATTGTGGGCGGAAACTTCC 
1 ATTGTGGGCGGAAACTTCC 
  
 
 
 
 
 
Jun/ATF2 TTGGGTAGCACAGCGA 
 
 
 
 
  
 
 
 
 
NF-κB/SP-1 ATGGTCTCTCCCCTC 
 
 
 
 
Egr/SP-1 TTTCTAAAGTGGGTG AGCAGGTTTTTAAC T
NF-AT TTTCTAAAGTGGGTG AGCAGGTTTTTAAC T
  
  
NF-κB ATAG A/C AAGTCCCCA 
 
 
 
 
 
 
 
Kasibhatla et al, 2000 
 
et
et
 
 
 
hwell, 1998;1999 
Weber et al, 1998; 199
Chow et al, 2000 
 
ann
et
 
 
 
 
Faris et al, 1998a and 1998b 
 
 
 
 
 
Li-Weber et al, 2000 
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Weber et al, 1999).  Interestingly, Egr2 and Egr3 are NF-AT targets themselves (Mittelstadt 
& Ashwell, 1998; 1999).  Moreover, another composite Egr/NF-AT site at -680 is now known 
to be recognized by both NF-AT and Egr1/Egr3 proteins (Li-Weber et al, 1999).  One 
transcription factor that belongs to the Egr family and shares a great degree of homology with 
Egr1 is the Wilms’ tumor 1 protein (WT1).  WT1 has been suggested to be required during 
haematopoiesis, and aberrant expression or mutations have been linked to impaired apoptosis 
and leukaemogenesis.    
 
 
 
5. The Wilms’ Tumor gene (WT1) 
d by positional cloning and sequencing in patients 
ith Wilms’ tumor (Call et al, 1990; Gessler et al, 1990).  Wilms’ tumor is a paediatric 
ed at 11p13, spans 50kb and is comprised of ten exons (Call et al, 1990; 
essler et al, 1990).  Its expression is highest during embryogenesis, where it is found in 
 
The Wilms’ tumor gene was first identifie
w
kidney malignancy, first described by Max Wilms in 1899, affecting 1 in 10,000 children 
below the age of 5 (Matsunaga, 1981). Wilms’ tumor is thought to arise through the 
uncontrolled proliferation of undifferentiated mesenchyma cells initially destined to become 
glomerular podocytes, which form the filtration barrier within the glomerolus (Beckwith, 
1998).  Wilms’ tumor is often observed in association with several rare malformation 
syndromes, of which most common are the WAGR syndrome (Wilms’ tumor, Aniridia, 
Genitourinary abnormalities and mental Retardation) (Pendergrass, 1976), the Denys-Drash 
syndrome (diffuse mesangial sclerosis, male pseudohermaphroditism and Wilms’ tumor) 
(Pelletier et al, 1991) and the Beckwith-Wiedemann syndrome (gigantism, macroglossia, 
omphalocele, hyperinsulinism and predisposition to several tumors like Wilms’ tumor) 
(Henry et al, 1991).   
 
The WT1 gene is locat
G
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multipotent progenitor cells of a restricted range of cells and tissues, mainly the genitourinary 
system (Pritchard-Jones et al, 1990; van Heyningen et al, 1990), the epicardium and 
subepicardial mesenchyme (Moore et al, 1999), the neurons (Wagner et al, 2002) and at early 
stages of haematopoiesis (Ellisen et al, 2001).  In adults, expression continues in specific cell 
types of the kidney and gonad, and in CD34+ progenitor cells of the bone marrow (Inoue et al, 
1997).  Mature human resting or activated T cells do not produce WT1.  The important role of 
WT1 during development is realized once WT1 is homozygously knocked out.  WT1 null 
mice die in utero at embryonic day 13 and they display complete agenesis of the kidneys, 
gonad, spleen and adrenal glands (Kreidberg et al, 1993; Herzer et al, 1999).   
 
A very interesting aspect of WT1 is that its 10 exons can undergo pre-mRNA splicing in 
everal ways.  Also, other alternative isoforms are derived from the use of an upstream and in 
e transcript variants is so far unknown, and different 
ariants are produced in different cell types and tissues.  However, four major splice variants 
s
frame CTG start codon, an internal ATG start codon at the end of exon 1 and a residue in 
exon 6 which is subject to RNA editing (Bruening & Pelletier, 1996; Scharnhorst et al, 1999; 
Discenza & Pelletier, 2004). Moreover, an alternative promoter within intron 1 was recently 
identified, which gives rise to the AWT1 transcript (Dallosso et al, 2004).  This transcript is 
paternally imprinted and has overlapping pre-mRNA splicing variants with WT1. All these 
splicing and translational events overall yield a great amount of splicing isoforms, with 36 
identified at the time of printing (Hohenstein & Hastie, 2006). 
 
6. Wilms’ Tumor-The Protein 
 
The function of the majority of thes
v
are always encountered in almost all cells where WT1 is expressed.  These arise from 
differential splicing of two splicing sites. The splicing site I is mammal-specific and involves 
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the whole of exon 5, which encodes a stretch of 17 amino-acids. The splicing site II involves 
the last three codons of exon 9, which encode for the three amino-acids lysine, threonine and 
serine (KTS) (Haber et al, 1991).  Overall these splicing events give rise to four splicing 
variants (Fig.I.5), which are attributed different but questionable cellular functions.   
 
Figure I.5.  Schematic representation of the WT1 mRNA. The mRNA of WT
splicing is depicted on the upper part. The bottom part contains the resulting transcr
1 before 
ipts after 
ifferential splicing of two major splicing sites, one including or excluding exon5 and one 
cluding or excluding the last three codons of exon 9 (KTS) (bottom).  Exons are shown in 
  WT1-/+ (WT1+KTS
sence or presence of the two splice inserts, WT1 encodes a protein of 52-
4 kDa that shares a high degree of structural homology with the early growth response (Egr) 
 WT1 protein possesses, it becomes apparent that 
ifferent splice variants could have different functions.  Therefore, the WT1-KTS variant, 
d
in
blue blocks and splicing sites in green.   
 
 
1 2 3 4 6 7 10 
KTS 
5 98
 
                    WT1+/+ 
    WT1+/- (WT1-KTS) 
Exon5 KTS 
  ) 
                        WT1-/- 
 
 
Depending on the ab
5
family of transcription factors (Rauscher et al, 1990).  At the C-terminus, WT1 has four C2H2 
zinc fingers at the, a pattern typical for DNA binding factors and a nuclear localization 
domain (Call et al, 1990; Gessler et al, 1990; Bruening et al, 1996). The N-terminus of WT1 
is  proline/glutamine rich and serves as a transactivation domain.  In addition, the N-terminus 
includes a self-association domain, a repressor domain and an RNA recognition motif (Wang 
et al, 1995; Herzer et al, 2001) (Fig.I.6).    
 
Considering the different domains that the
d
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containing all the prerequisites for a DNA binding protein with transcriptional regulatory 
abilities, is thought to be a transcription factor (Davies et al, 1998).  Several studies have 
shown that WT1-KTS can act both as a transcriptional activator and repressor depending on 
the promoter, cell type and cell cycle stage (see below).  The addition of the three amino-acids 
between zinc fingers three and four in the WT1+KTS variant, changes the spacing between 
the last two zinc fingers, reduces its affinity for DNA binding and as a result WT1+KTS is not 
attributed transcription factor activities (Laity et al, 2000).  However, it is thought that 
WT1+KTS is involved in RNA processing as it has a higher affinity for RNA (Kennedy et al, 
1996). Also, it has been shown to co-localize with RNA speckles and splicing factors in the 
nucleus (Larsson et al, 1995).  Not much is known about the 17 amino-acid inclusion or 
exclusion in the protein but it has recently been suggested that the WT1+/- variant has an anti-
apoptotic function on the intrinsic apoptosis pathway in some leukaemias (Ito et al, 2006).  
However, mice homozygous for exon 5 deletion develop normally and are fertile 
(Eggenschwiler et al, 1997). 
 
the different domains of inte
Figure I.6.  Schematic representation of the WT1 protein.  (A) WT1 protein annotated for 
rest.  The splicing sites are also depicted in turquoise. (B) Pdb 
Representation of the putative way WT1 can coil around the DNA.  The zinc ions are depicted 
s blue spheres and an iron atom in green. 
) 
       
             
a
 
A)                                                                              
                        
 
 
 
 
B
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Moreover, the ratio between the WT1-/+ KTS is of importance.  It is conserved among tissues 
) and any imbalanced expression will lead to developmental abnormalities 
. WT1-KTS transcription targets and protein collaborators 
ds to the GC-rich 
anonical Egr1 DNA binding motif -GCG(5)CG- (Rauscher et al, 1990) but also to TC-rich 
(Haber et al, 1991
(Hammes et al, 2001).  This is reflected in transgenic mice experiments. When the WT1+KTS 
isoform is selectively omitted the animals display a phenotype reminiscent of Frasier 
syndrome in humans (glomerulopathy and male-to-female sex reversal).  When the WT1-KTS 
isoform is selectively deleted, the malformations in the mice are more severe, characterized 
by hypoplastic kidneys and streak gonads.  It is worth pointing out though, that unlike the 
completely WT1 null mice, both the WT1+KTS and WT1-KTS transgenic mice survive to 
birth, indicating a functional overlap between the two isoforms (Hammes et al, 2001). 
 
 
7
 
Belonging to the Egr family of transcription factors, WT1-KTS usually bin
c
regions -(TCC)4TCTCC- (Wang et al, 1993).  The identification of bona fide WT1-KTS 
target genes, however, is a difficult process as a result of isoform and context-specific 
regulatory activities of WT1.  The transcription factor WT-KTS variant has a growing list of 
candidate target genes.  The best characterized transcriptional relationships of WT1-KTS and 
its target promoters are summarized in table I.2. 
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Table I.2.  Summary of the best studied putative genes that WT1-KTS regulates at the transcriptional       
level 
Gene promoter target                          Reference 
Gonad 
Dax1↑                                             Kim et al, 2002 
               Sf1↕                                                 Wilhelm & Englert, 2002 
               Wnt4                                                Sim et al, 2002 
              *
                MIS↑                                               Nachtigal et al, 1998 
Kidney 
            AREG↑                                             Lee et al, 1999 
              *CDH1↑                                            Hosono et al, 2000 
Podocytes 
1             PODX↑                                             Palmer et al, 200
              NPHS1↑                                            Wagner et al, 2004 
Cell cycle 
            p21↑                                                  Englert et al, 1997 
              cyclinD1↑                                          Tuna et al, 2005 
              cyclinE↓                                             Loeb et al, 2002 
Apoptosis 
            Bcl-2↕                                                Mayo et al, 1999 ; 
3 
↑                                                 Morrison et al, 2005 
    
                                                                         Cheema et al, 200
              *Bak
              EGFR↓                                               Englert et al, 1995a
Transcription  
            *c-Myc↓                                             Han et al, 2004 
            *WT1↓                                               Rupprecht et al, 1994 
              *Egr1↕                                                Madden et al, 1991 
                 Pax2↓                                                Ryan et al, 1995
Genes marked w nscriptional effect,  
↑ activation, ↓sup
 
s research on the field of WT1 progresses, it becomes clearer that the distinct effects of 
T1 are mediated by the association of WT1 with other factors.  WT1-KTS is usually found 
ith an asterisk are target at an Egr1 binding site.  Arrows depict the tra
pression and ↕ for both.  
 
A
W
to be contained in complexes composed of either DNA-binding proteins or non-DNA-binding 
proteins.  One example of the interaction of WT1 with a DNA-binding protein is its 
collaboration with p53.  Both proteins co-immunoprecipitate and WT1 enhances p53 DNA 
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binding by stabilizing p53 (Maheswaran et al, 1995).   Transgenic mice experiments have also 
shown that p53 enhances WT1-mediated transcriptional repression (Menke et al, 2002).  
Others include SF1 (Nachtigal et al, 1998), CBP and p300 (Wang et al, 2001).  A non-DNA 
binding protein that indirectly, by interacting with WT1, affects gene transcription, is Par-4.  
Par-4 has been shown to interact with WT1 by the yeast-two-hybrid system (Johnstone et al, 
1996) and that a direct interaction with the zinc fingers of WT1 augments transcriptional 
repression by WT1 (Richard et al, 2001).  Other non-DNA-binding proteins that interact with 
WT1 include Hsp70 (Maheswaran et al, 1998), WTIP (Srichai et al, 2004) and BASP1 
(Carpenter et al, 2004). 
 
 
8. WT1 and leukaemia: a tumor suppressor or an oncogene? 
 the existence of 
ifferent splice isoforms, which have different functions and are differentially expressed, but 
 
The complexity in understanding the biology of WT1 is not only due to
d
is also reflected in WT1’s controversial role in leukaemogenesis.  Although WT1 was first 
identified in Wilms’ tumors because of mutations (Haber et al, 1990), it is now known that 
only 10% of the Wilms’ tumors actually have mutations in the gene (Coppes et al, 1993; 
Gessler et al, 1994).  For this reason it is thought that other loci may be involved, e.g., FWT1 
(Rahman et al, 1996).  An interesting observation was that Wilms’ tumor patients develop 
leukaemia as a second primary tumor (Moss et al, 1989; Pritchard-Jones et al, 1994).  In 
addition, leukaemias are also common in relatives of children with Wilms’ tumor.  The 
involvement of WT1 during early haematopoiesis and its very high expression in more 
undifferentiated progenitor CD34+/CD33- cells (100-fold more than in differentiated 
precursors CD33+) (Maurer et al, 1997) raises the question on whether WT1 is also implicated 
in leukaemogenesis. 
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Research trying to provide an answer has been contradictory.  On one hand, WT1 has been 
found to be mutated in sporadic leukaemia at a rate of 10%, which is comparable to Wilms’ 
, WT1 has been awarded an oncogenic role, as it has been shown to be 
verexpressed in acute leukaemic cell lines and acute leukaemias of myeloid and lymphoid 
. WT1 and its controversial role in apoptosis 
 the indications that WT1 promotes 
ell proliferation and inhibits apoptosis (Yamajami et al, 1996, Loeb & Sukumar, 2002), 
tumors and at a rate of 15% in AML patients (King-Underwood et al, 1996).  Most of the 
mutations identified resulted in zinc-finger loss.  Such a C-terminally truncated WT1 protein 
would lose its DNA binding ability but would retain its protein-protein interaction capacity, 
having, however, its usual function altered.  Interestingly, it has been suggested that even 
heterozygous mutations are sufficient to contribute to leukaemogenesis (King-Underwood & 
Pritchard-Jones, 1998).  This can be explained, if the result of the mutation is a truncated 
protein that can still self-associate. Such an event has been shown to alter the subnuclear 
localization of the wild-type protein and produce WT1 proteins that act in a dominant-
negative manner (Englert et al, 1995b).  These characteristics give WT1 a tumor suppressor 
function, which results in leukaemogenesis when lost due to mutation during early 
haematopoiesis.   
 
On the other hand
o
origin (Inoue et al, 1997, Menssen et al, 1995). High expression of WT1 has been found to 
correlate with less-differentiated phenotypes (Pritchard-Jones & King-Underwood, 1997).  
This overexpression has been suggested to be isoform-dependent as it has been connected 
with an excess of the exon-5 containing WT1 variant (Renshaw et al, 1997).   
 
 
9
 
The oncogenic potential of WT1 is further supported by
c
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hypothetically through upregulation of anti-apoptotic Bcl-2 (Mayo et al, 1999) and cyclin D1 
(Tuna et al, 2005).  In other cases, when WT1 expression is lost in leukaemic cell lines or in 
the knock-out mouse, apoptosis is enhanced (Algar et al, 1996; Herzer et al, 1999).  In 
contrast, expression of the WT-KTS variant has induced G1 arrest and apoptosis in 
myeloblastic leukaemia cells (Murata et al, 1997) and has been shown to induce apoptosis by 
upregulating pro-apoptotic Bak (Morrison et al, 2005).  Therefore, WT1 may act either as a 
‘survival factor’ by preventing apoptosis of transformed cells or it may induce apoptosis and 
hence prevent the proliferation of leukaemic cells.  However, there are no clearly described 
pathways that explain how WT1 is able to affect such opposing mechanisms. 
 
10. Aim of study 
 
The role of WT1 in leukaemogenesis is unclear.  However, it is apparent that WT1 plays a 
ery important role in apoptosis.  Therefore, depending on its expression profile during v
haematopoiesis, it can direct the cell either towards apoptosis or towards proliferation.  In the 
unlucky event of a cell turning cancerous, the eventual expression of WT1 could act as a 
prevention mechanism by instructing apoptosis.  On the contrary, the presence of loss of 
function mutations in WT1 would abolish its latter ability and then the cell would be free to 
survive and continue its carcinogenesis, eventually leading to leukaemia.  Furthermore, if 
WT1 expression continues or restarts after the haematopoietic stages where it is actually 
required, then this would give the cell a proliferative advantage, promoting in this way 
leukaemogenesis.  As already mentioned, all these events have been described, making it 
difficult for researchers to characterize WT1’s exact function.  Currently, opinions tend to 
support WT1 overexpression in leukaemias, so that WT1 is being considered as a target 
marker for immunotherapy (Inoue et al, 1994; Inoue et al, 1996; Oka et al, 2000; Gao et al, 
2000).  One should be cautious, as most research is based on detecting WT1 expression by 
 22
K.Bourkoula  I Introduction 
reverse-transcriptase polymerase chain reaction against the C-terminus of the WT1 transcript, 
and not by protein analysis.   
 
The role of WT1 in apoptosis induction of human T-cell leukaemias or leukaemic cell lines 
as not been extensively studied.  It provides a very interesting and challenging field of 
 
h
research, taking into consideration that WT1 is a transcription factor that binds to the Egr1 
consensus and is involved in haematopoiesis and apoptosis.  The CD95L is important for the 
apoptosis of mature T cells and there is also evidence that it participates in intrathymic 
apoptosis during T cell development. In addition the CD95L contains three sites where Egr1 
has been shown to bind on its promoter.  Therefore, the aim of this work was to study the 
expression of WT1 in leukaemic T-cell lines and its mutation status.  In addition, analysis of 
the connection between WT1 presence/absence with T cell apoptosis was implemented and 
finally the role of WT1 in the function of the CD95/CD95L system was studied. 
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II Materials and Methods 
II.1 Materials 
 
1.1 Buffers.   
All chemical substances used, were obtained from Sigma-Aldrich unless otherwise stated. 
 
Buffer Composition 
Buffer A (nuclei extract) 10mM HEPES pH8.0, 0.5M sucrose, 50mM NaCl, 0.25mM EGTA, 1mM 
EDTA, 0.5mM spermidine, 0.5% Triton x-100, 1μg/ml trypsin and a 
100mM solution in isopropanol of 0.5mM PMSF, 0.5μg/ml leupeptin, 
0.7μg/ml pepstatin, 1μg/ml aprotinin and 40μg/ml bestatin 
Buffer B (nuclei extract) 10mM HEPES pH8.0, 25% glycerol, 500mM NaCl, 0.1mM EGTA, 0.1mM 
EDTA, 05mM spermidine, 0.25mM DTT and a 100mM solution in 
isopropanol of 0.5mM PMSF, 0.5μg/ml leupeptin, 0.7μg/ml pepstatin, 
1μg/ml aprotinin and 40μg/ml bestatin 
TE 10mM Tris pH 8.0, 1mM EDTA 
Solution 1 (plasmid isolation) 50mM glucose, 25mM Tris pH 8.0 and 10mM EDTA 
Lower Gel buffer (western blot) 1.5M Tris pH 8.8, 0.4% SDS 
Upper Gel buffer (western blot) 0.5M Tris pH 6.8, 0.4% SDS 
10xSDS Running buffer 0.025M Tris, 0.19M glycin, 1% SDS 
Semi Dry buffer 0.045M Tris, 0.035M glycin, 5% MeOH  
SDS sample buffer (loading) 0.0625M Tris, 50mM DTT, 2.3% SDS, pH 6.8, 0.1% Bromophenol blue 
(SDS) wash-buffer 0.02M Tris pH 7.3, 0.15M NaCl, 0.01% Tween-20 
DNA-binding buffer (EMSA) 50mM HEPES pH 7.5, 100mM NaCl, 2mM EDTA, 20% glycerol  
Luciferase Buffer 1.07mM (MgCO3)4 Mg(OH)2·5H2O, 668mM tricine, 100mM MgSO4, 
10mM EDTA, 1M DTT, 4mM CoAOAc, 100mM ATP, 5mg luciferin  
PBS 8g NaCl, 0.2g KCl, 1.44g Na2HPO4, 0.24g KH2PO4 
TBE (10x) 108g Tris, 55g Boric acid, 40ml EDTA pH 8.0 (0.5M) 
ACK 41.45g NH4Cl, 5g KHCO3, 0.186g EDTA, in 500ml volume with H2O, pH 
7.27 
RIPA 120mM NaCl, 50mM Tris/HCl (pH 8.0), 1% NP-40, 0.5% Desoxycholate, 
1mM PMSF, 25mM NaF, 0.1% SDS, 200μM Na3VO4, 1mM DTT, 
protease inhibitors (tablet of complete) and H2O to the appropriate volume 
Nicoletti buffer PBS buffer, 0.1% SodiumCitrate, 0.1% TritonX-100 
Propidium Iodide Propidium Iodide in PBS 2mg/ml 
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1.2 Media  
 
Medium Composition 
Bacterial Culture 
                         LB (10x) 
                                                  90g Bacterial Tryptone (Roth), 45g Yeast extract (Gerbu),     
                                                  90g NaCl, 900ml H2O                                 
                        LB-Agar 
                                                   450μl (1x) LB, 9g Agar 
Human Cell Culture 
                        RPMI 
                                                   900ml RPMI (Invitrogen), 10% FCS (Gibco), 10mg/ml Gentamicin (Gibco) 
                        DMED 
                                                   500ml DMED (Invitrogen), 10% FCS (Gibco), 1μg/ml Puromycin, 1μg/ml        
                                                   Tetracyclin, 0.5mg/ml G418 
 
 
1.3 Antibodies 
Protein Target Antibody Secondary Antibody 
 
(F-6) sc-7385 (Santa Cruz Biotechnology) 
 
Mouse monoclonal  
(Santa Cruz Biothechnology) 
(C-19) sc-192  (Santa Cruz Biotechnology) Rabbit Polyclonal 
(Santa Cruz Biotechnology) 
(H-10) sc-7341  (Santa Cruz Biotechnology) Mouse monoclonal  
(Santa Cruz Biotechnology) 
Western Blot 
WT1 N-terminus 
 
WT1 C-terminus 
 
YY1 
 
Tubulin Monoclonal anti-α-tubulin (Sigma) Mouse monoclonal  
(Santa Cruz Biotechnology) 
 
(C-19) sc-189 (Santa Cruz Biotechnology) 
 
- 
(F-6)X  sc-7385 (Santa Cruz Biotechnology) - 
EMSA 
Egr-1 
 WT1 
   Sp1 (PEP2) X sc-59 (Santa Cruz Biotechnology) - 
Fas-ligand (Nok-1) Purified mouse anti-human fas ligand  
(BD Pharmingen) 
Mouse monoclonal IgG1 
(BD Pharmingen) 
IgG1 (anti-TNP) Purified mouse IgG1,κ, isotype 
control  (BD Pharmingen) 
- 
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1.4 Cell Lines 
 
Jurkat16, Jurkat 282, Molt4, CEM, Myla, SeAx and HH are human T-cell leukaemic cell lines. 
Hut78 is a human T-cell lymphoma.  All cell lines were cultured in RPMI medium.  The cell line 
U2OS is an osteosarcoma cell line in which WT1 expression is inhibited by the presence of 
tetracycline (Haber et al, 1996).  U2OS cells were cultured in DMEM medium. Tetracycline was 
removed from the medium for at least 48h prior of experiments to allow WT1 expression.  All 
cells were grown at 37ºC in a humidified 5% CO2 incubator. 
 
1.5 Oligonucleotide primers used for cDNA amplification (Qiagen) 
PCR Parameters Target 
Gene 
Sequence 
Annealing 
Temp 
No of Cycles 
WT1-A 
 
5'-GCCCAATACAGAATACACA-3' forward 
5'-TCACACACTGTGCTGCCT-3'  reverse 
56.5°C 30 
WT1-B 5'-CCCAACCACTCATTCAAG-3' forward 
5'-TATTCTGTATTGGGCTCCGC-3' reverse 
67°C 25 
WT1-C 5'-CTAACGCGCCCTACCTGCCC-3' forward 
5'-GGTGCAGCTGTCGGTGGGGG-3' reverse 
57°C 40 
CD95 5'-CAAGTGCAGATGTAAAC-3' forward 
5'-TGAAGTTGATGCCAATTACG-3' reverse 
58°C 30 
CD95L 5'-ATAGGATCCATGTTTCTGCTCTTCCACCTACAGAAGGA-3' 
forward 
5'-ATAGAATTCTGACCAAGAGAGGCTCAGATACGTTGAC-3' 
reverse 
58°C 30 
β-actin 5'-TGACGGGGTCACCCACACTGTGCCCATCTA-3' forward 
 
5'-CTAGAATTTGCGGTGGACGATGGAGGG-3' reverse 
60°C 20 
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1.6 Oligonucleotide primers used for quantitative real-time PCR (Eurogentec) 
 
Target Gene Sequence 
5'-ACTGTGACCCTTGCACCAAAT-3' forward 
5'-GCCACCCCAAGTTAGATCTGG-3' reverse 
CD95 
5'-AATCATCAAGGAATGCACACTCACCAGCA-3' probe 
5'-AAAGTGGCCCATTTAACAGGC-3' forward 
5'-AAAGCAGGACAATTCCATAGGTG-3' reverse 
CD95L 
5'-TCCAACTCAAGGTCCATGCCTCTGG-3'probe 
5'-ACCCACACTGTGCCCATCTACGA-3' forward 
5'-CAGCGGAACCGCTCATTGCCAATGG-3' reverse 
β-actin 
5'-ATGCCCTCCCCCATGCCATCCTGCGT-3'probe 
 
 
 
1.7 Oligonucleotide Probes used for EMSA (Qiagen) 
 
Gene promoter site Sequence 
CD95L -120 5'-TCAGCTGCAAAGTGAGTGGGTGTTTCTTTGAG 
CD95L  -180  5'-ATTGTGGGCGGAAACTTCCAGGGG 
CD95L -680 5'-GATCTAATTTCTAAAGTGGGTGTAGCAGGTTTTTAAC 
NFY 5'-CACCTTTTAACCAATCAGAAAAAT 
 
 
 
1.8 Vectors  
 
Vector Origin 
pRc/CMV Invitrogen 
pCR-Blunt II-TOPO Invitrogen 
CMV_WT1-CA Englert C. (Herzer et al, 2001) 
CMV_WT1-CC Englert C. (Herzer et al, 2001) 
pTATA_Luc Li-Weber et al, 1998 
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II. 2 Methods 
  
2.1 Plasmid isolation 
 
The plasmids that were screened for positive clone content were purified according to the 
following protocol:  2ml of an overnight LB culture were centrifuged at 6000rpm for 5 mins and 
the cell pellet was resuspended in 350μl of solution 1 with the addition of 25μl of lysozyme 
(10mg/ml in 10mM Tris pH 8.0).  Cell lysis was allowed to take place for 2 mins at room 
temperature and then the lysozyme was heat-inactivated at 95°C for 60 sec.  The samples were 
then spun down at 13.000rpm for 10mins and the supernatant was mixed with 40μl Na-acetate 
(2.5M) (Roth) and 420μl isopropanol and stored at -80°C for 15mins.  The samples were then 
allowed to warm up to room temperature and a centrifugation step at 13.000rpm for 15mins 
produced a DNA containing pellet.  The pellet was washed once with 70% ethanol and the 
samples were vacuum dried.  The final pellet was resuspended in 30μl of TE buffer. 
The plasmid constructs destined for sequencing of their inserts were purified and isolated with a 
Qiagen Plasmid Midi Kit according to manufacturer’s instructions.   All other plasmid constructs 
were isolated with a Nucleobond Plasmid Maxi purification kit following the manufacturer’s 
protocol.   
 
2.2 Total mRNA extraction 
 
The mRNA isolation and purification was carried out using the NucleoSpin RNA II kit 
(Macherey-Nagel).  Briefly, 1x106-1x107 cell were used.  The cell pellets were washed once in 
PBS and then homogenized in 350μl of RA1 buffer and 3.5μl of β-mercaptoethanol.  The mixture 
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was applied on a filter provided and after 1 min centrifugation the flowthrough was mixed with 
350μl 70% Ethanol and transferred into a fresh tube.  After a short spin, 350μl of membrane 
dissolving buffer (MDB) were added on the filter and the samples were again spun down for 1 
min.  The samples were then incubated at room temperature for 15mins in 95μl of DNase solution 
(90μl DNase buffer with 10μl DNase).  200μl of RA2 buffer were added (inactivating the DNase) 
followed by another round of brief centrifugation.  The samples were washed using  600μl of 
RA3 buffer.  After a short spin another 250μl of RA3 buffer were added and 2 min centrifugation 
followed.  Finally, mRNA was eluted from the filter with 40μl of RNase-free water.  This last 
step was repeated to optimize the concentration of the eluate.  The mRNA samples were stored at 
–80°C. 
 
2.3 Reverse-Transcription reaction for cDNA generation (RT) 
 
1μg of DNase treated RNA was reversed transcribed into cDNA with 50 U MuLV reverse 
transcriptase (Roche) in the presence of 50μM oligo-d(T) and 200nM dNTPs at 42ºC for 45mis. 
Aliquots (¼) of the resulting cDNA were then used as template for PCR amplifications. 
 
2.4 Polymerase Chain Reaction (PCR) 
2.4.1 PCR for plasmid DNA amplification 
All PCRs on plasmid DNA were carried out using Taq DNA polymerase (BioLabs)   in a typical 
PCR (total 40μl) as follows: 
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 0.5μl Taq DNA polymerase
31.5μl  Sterile H2O 
  4μl   10xPCR Buffer 
  1μl    Forward Primer 
  1μl   Reverse Primer 
  1μl  plasmid DNA (2μg) 
  1μl   dNTPs 
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2.4.2 PCR for cDNA amplification 
The amplification of the C-terminus of WT1 and all other cDNA amplifications were carried out 
using Taq DNA polymerase in a 40μl reaction according to the following protocol: 
 
28.5μl  Sterile H2O 
 4μl   10xPCR Buffer 
 1μl   Forward Primer 
 
 
 1μl  Reverse Primer 
 5μl cDNA 
 0.5μl  Taq DNA polymerase (2.5U)
 
 
 
For the amplification of the GC-rich N-terminus of WT1, the GC-Rich PCR system (Roche) was 
used according to manufacturer’s protocol.  This system uses a combination of two polymerase 
enzymes, the Taq DNA and Tgo DNA polymerases, providing higher fidelity, yield and 
specificity than using Taq alone.  Two different reactions (I and II see below) were carried out 
separately and mixed just before amplification. 
 
 
 
 
 
GC-Rich PCR reaction I (Total 35μl): 
 1μl  dATP (200μM) 
 1μl  dCTP (200μM) 
 1μl  dTTP (200μM) 
 1μl  dGTP (200μM) 
 1μl 
GC-Rich PCR reaction II (Total 15μl): 
 1μl  GC-Rich PCR System Enzyme mix (2U/50μl) 
 4μl  H2O 
10μl  5xGC-Rich buffer with DMSO (1.5mM MgCl2)
 
Forward primer (200nM) 
 1μl  Reverse primer (200nM) 
10μl  GC-Rich resolution solution (1M)
 xμl  cDNA (25-50ng) 
 xμl  H2O 
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2.5 Cloning 
2.5.1 Cloning reaction 
 
Cloning of the amplified transcripts for subsequent sequencing was done using the Zero Blunt 
Topo PCR Cloning Kit (Invitrogen life technologies), which provides the direct insertion of 
blunt-end PCR products in the pCR-Blunt II-TOPO vector using the topoisomerase I enzyme 
from Vaccinia virus.  All reactions were carried out according to the manufacturer’s instructions 
and incubated at room temperature for 5mins.   
Cloning Reaction (Total 6μl): 
2μl  Blunt-end PCR product 
1μl  Salt solution (1.2M NaCl, 0.06M MgCl2) 
2μl  Sterile water 
1μl  pCRII-Blunt-TOPO vector 
 
 
 
 
 
 
 
 
2.5.2 Transformation 
 
Transformation of the plasmids was done in chemically competent DH5a-E.coli.  2μl of the 
TOPO cloning reaction were introduced into 50μl of competent bacteria and the mixture was 
incubated on ice for 30mins.  The cells were then heat-shocked at 42°C for 30sec prior to transfer 
to ice.  250μl of S.O.C. medium were added and the reactions were incubated at 37°C for 1h with 
horizontal shaking.  Finally, 50μl from each reaction were spread on agar plates containing 
50μg/ml kanamycin.  The plates were incubated overnight at 37°C to allow colony formation. 
 
2.5.3 Positive clone selection 
After the overnight incubation and the appearance of clones, approximately 24 clones were 
selected from each reaction plate for analysis.  Each single colony was allowed to grow overnight 
in a liquid agar culture containing kanamycin (50 μg/ml), followed by isolation of  the plasmid.  
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After plasmid isolation, successful insertion was tested by restriction analysis using the EcoR1 
enzyme (Fermentas GMBH), which has two restriction sites on the vector flanking the PCR 
insertion position.  This directly allows the screening of the clones, as agarose gel electrophoresis 
of the enzyme digested reactions would yield a product of the exact size as the original PCR 
amplified product in a positive clone. 
 
2.5.4 Fill-in reaction to produce “blunt ends” 
The amplified PCR reactions of the cDNA destined for cloning contained mostly product with 
sticky ends.  Since the cloning vector is designed for blunt-end ligation, the sticky ends needed to 
be converted into blunt ends.  This was done by filling in the sticky ends with the complementary 
nucleotides.  A typical fill-in reaction is described below (total 20μl) and samples were incubated 
at room temperature for 30mins:   
 
 
 
 
 
2.5.5 Restriction digestion 
Restriction digestion of plasmid DNA was carried out at 37°C for 1h and 20 mins using the 
following protocol: 
10μl H2O 
 3μl plasmid DNA (mini-lysate) (20ng) 
 2μl Buffer (10x) 
 0.02μl RnaseA 
11μl H2O 
 0.5μl enzyme 
5μl PCR product 
 2μl Buffer (200mM Tris, 100mM MgCl2, pH 7.6) 
 2μl dNTPmix (10mM) 
 1μl Klenow fragment (Fermentas) 
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2.5.6 Competent cell preparation 
 
The strain to be made competent was set at 5ml in an overnight liquid Agar culture.  After the 
overnight growth, 2ml of the culture were inoculated with 100ml of L-Broth and allowed to grow 
further at 37°C with shaking.  Samples of the culture were taken at regular intervals and OD600 
of the cells was measured.  Growth was stopped when the OD600 reached a value of 0.42-0.45 
(indicating sufficient growth).  The cells were then placed on ice for 5 mins and 100ml of the 
culture were spun at 6000rpm for 5 mins.  The pellet was resuspended in 40ml of ice-cold CaCl2 
(0.1M).  The cells were re-pelleted, gently resuspended in 25ml of ice-cold CaCl2 (0.1M) and 
incubated on ice for 30 mins.  The cells were pelleted again prior to resuspension in 1ml of ice-
cold CaCl2 (0.1M).    Finally, 15% (v/v) sterile glycerol was added and 50μl aliquots were frozen 
in liquid N2 and stored at -80°C. 
 
2.6 Western blot analysis 
 
2.6.1 Protein extraction 
Whole cell lysates were prepared for protein extraction for western blot analysis.  Usually 1x106-
1x107 cells were used, the pellet of which was washed once in ice cold PBS and then resuspended 
in 100-250μl of radioimmunoprecipitation assay (RIPA) buffer.  An incubation of 20 mins at 4°C 
was followed with vortexing, and the cells were centrifuged for 20mins at 4°C at 13.000rpm.  
The supernatant was then transferred to a fresh tube and th protein concentration was determined 
using the BCA Protein Assay kit according to manufacturer’s instructions (PerBio, Pierce).  20-
50μl of 5x sample loading buffer were added to the sample, corresponding to 20-25μg protein in 
each sample.  Finally, the samples were incubated at 95°C for 10mins and were stored at -20°C.   
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2.6.2 Nuclear protein extraction 
1x108 cells were used for each preparation.  The cell pellet was recovered by centrifugation at 
1200rpm for 10mins and used immediately.  All reactions were performed at 4°C.  The cell pellet 
was resuspended in Buffer A (10x volume) and after vigorous vortexing the nuclei were collected 
by centrifugation at 3500 rpm for 5mins.  Nuclei were resuspended again in Buffer A (10x 
volume) and another step of centrifugation at 4000rpm for 5mins was carried out.  Then the 
supernatant was carefully removed and the pellet was resuspended in 500μl of Buffer B.  Each 
sample was incubated at 4°C with stirring for 30mins and the supernatant was collected by 
centrifugation at 13000rpm for 10mins, and it was stored at -80°C for future usage.  
Determination of protein concentration was carried out with the BCA Protein Assay kit according 
to manufacturer’s instructions (PerBio, Pierce). 
 
2.6.3 SDS-PAGE 
 
For a 10% SDS-page gel, 2ml of lower gel buffer were mixed with 3.3ml of H2O, 2.6ml of 30% 
Acrylamide, 50μl of 10% APS and 5μl of TEMED.  Approximately 7ml were poured in the glass 
plates where the gel would be mounted to set. On top of the set lower gel, a stacking gel was 
poured which was made of 1.25ml of upper gel buffer, 3ml H2O, 0.8ml of 30% Acrylamide, 50μl 
of 10% APS and 5μl of TEMED.  Combs of the required well size and number were added and 
the gel was allowed to set. 
 
2.6.4 Western blot  
For nuclear extract protein analysis 20-25μg of protein were mixed with 5xSDS-sample loading 
buffer, and the samples were boiled for 5mins at 95°C.  For whole cell lysates, 20-25μg of 
already pre-mixed with loading buffer were boiled for 10mins at 95°C.  The boiled samples were 
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loaded in the well of a mini-gel (20-25μg of protein) along with 15μl of pre-stained SDS-protein 
marker (NewEngland BioLabs) and one mini-gel was run at 35mA.  The gel was then blotted 
with semi-dry buffer on a transfer membrane in a blotting chamber (BioRad) for 1h and 20 mins 
at 60mA.  After transfer the membrane containing the proteins was removed from the chamber 
and blocked with 5% milk (milk poweder in wash-buffer) for 1h at room temperature.  Then it 
was washed three times (10mins each) with wash-buffer and the antibody was applied in 5% BSA 
for 1h at room temperature(WT1-C19, YY1, Tubulin) or overnight at 4°C (WT1-F6 antibody) on 
a horizontal rocker.  After another round of washes as before, the appropriate secondary antibody 
was applied in 5% milk in a dilution 1:10.000 for 1h at room temperature.  The membrane was 
washed with wash-buffer once more and placed in a film cassette for developing.  The 
chemiluminescence reagents ‘enhanced luminol’ and ‘oxidizing reagent’ (1:1) (PerkinElmer Life 
Sciences) and an X-ray film (Kodak) was applied. 
 
 
2.7 Electrophoretic Mobility Shift Assay (EMSA) 
 
2.7.1 Primer annealing 
First, oligonucleotide probes were annealed for labeling.  This was carried out by mixing 20μg of 
sense and anti-sense oligonucleotides with 5μl of Tris/MgCl2 (200mM pH 7.5), 10μl of KCl 
(800mM) (AppliChem) and H2O to a final volume of 100μl.  The mixture was incubated at 90°C 
for 2 mins and then placed in a water bath of 70°C initial temperature that was allowed to cool 
down to room temperature.   
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2.7.2 Labeling  
300ng of annealed oligonucleotides were labeled radioactively in a reaction using 2μl of Tris 
(200mM pH 7.5)/ MgCl2 (100mM), 17μl of ddH2O, 0.25μl dGTP, dCTP, dTTP (4mM), 1μl of 
Klenow fragment and 2.5μl of 32P-dATP.  The reaction was allowed to take place at 37°C for 40 
mins.  The unlabeled probe was removed by precipitation with 10μg/μl tRNA, 4M NH4Ac (1:1 
v/v) and 70% ethanol (2v), the resulting pellet was washed in 70% ethanol and after drying the 
labeled oligonucleotides were resuspended in 50μl of TE buffer.   
 
2.7.3 Binding reaction 
The labeled and purified oligonucleotides were set for protein binding in a reaction that contained 
1-1.5μl of labeled oligonucleotides (30-50 counts), 1.5μl of dI-dC (200ng/μl), 8μl of DNA-
binding buffer, 12μl of ddH2O and 8-20μg of protein (nuclear extract) or recombinant protein.  
The WT1+/- KTS recombinant proteins have been described before (Elser et al, 1997).  The 
binding reaction was carried out at room temperature for 30 mins.  For supershift assays, before 
the addition of the radioactively labeled oligonucleotides, the sample was incubated with the 
antibody of interest (1-2μg) on ice for 30mins.   
 
2.7.4 EMSA loading 
The samples were run onto a 30% polyacrylamide gel [7.5ml of 30% polyacrylamide (0.8% Bis) 
with 5ml TBE (5x), 37,5ml ddH2O, 0.4ml 10% APS and 50μl TEMED].  The gel had a thickness 
of 1.5mm and was run at 150V of constant voltage, for 1.4-1.6h. The gel was then transferred 
onto a Whatman membrane and vaccum-dried at 80°C for 1-2h.  Afterwards, the membrane with 
the gel were placed in cassette for radioactive exposure along with an X-ray film (Kodak) and 
exposure was carried out overnight at -80°C.  The film was developed the following day. 
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2.8 T cell preparation 
 
2.8.1 T cell isolation 
 
For primary T cell isolation, 30ml of blood were poured gently on 15ml Biocoll Separating 
solution and were centrifuged for 20mins at 2420rpm at 20°C.  The supernatant (containing T 
cells) was carefully removed with a pipette and placed in a fresh tube where the volume was 
added up to 50ml with RPMI medium (without additives).  The cells were centrifuged for 10mins 
at 1500rpm and the T cells now present in the pellet were cleared off the supernatant.   Next was 
the monodepletion step, which would permit all monocytic cells to adhere and hence B and T cell 
would remain in solution.  This was done by resuspending the previous cell pellet in RPMI  and 
allowing to rest overnight.  After monodepletion, the supernatant was isolated and the total 
concentration was brought down to 8x106 cells/ml by spinning down at 1500rpm for 5mins and 
dissolving the pellet in fresh medium (50ml).  This was then divided in two tubes of 25ml each 
and then an equal volume of Erythrocytes was added.  The cells were mixed well and centrifuged 
at 1000rpm, low brake, for 10mins at 20°C.  Most of the supernatant was removed and only 20ml 
were left, in which the pellet was resuspended.  Then 15ml of Ficoll were added on top carefully 
and the sample was spun down at 2420rpm for 20mins at 20°C.  The supernatant (containing B 
cells) was discarded and the erythrocytes in the pellet (containing T cells and erythrocytes) were 
lyzed with ACK lysis buffer.  Lysis was stopped when the characteristic clear cherry red colour 
appeared, with RPMI medium.  The mixture was centrifuged for a last time at 1500rpm for 5mins 
and only T cells are left. 
 
 
 
 
 37
K.Bourkoula  II Materials and Methods 
2.8.2 Erythrocyte preparation (2% sheep Erythrocytes) 
 
25ml of Erythrocytes were washed 3-4 times with RPMI after the final spin at 1200rpm for 10 
mins at 20°C, the pellet was resuspended in AET solution and incubated for 15 mins at 37°C, 
rolling.  Then the pellets were washed 4-5 times in PBS and the final pellet was resuspended in 
RPMI (FCS added) yielding a 2% erythrocyte solution.     
 
2.9 Transfection of Jurkat T cells 
Jurkat T cells were transfected with two different protocols depending on the aim of the 
transfectants.  For luciferase analysis Jurkat cells were transfected with electroporation and for 
transient transfection with WT1 expressing constructs, Jurkat cells were transfected with Amaxa 
nucleofection.   
 
2.9.1 Electroporation 
For electroporation 1x107 cells were used for each transfection, and each transfection was carried 
out in duplicates.  The cells were spun down at 1500rpm for 5 mins at 20°C and the cell pellet 
was resuspended in 400μl of RPMI.  The appropriate plasmid DNA was added (two plasmids for 
co-transfection) experiments and after mixing gently with the pipette the sample was poured in a 
cuvette for this volume.  Electroporation was done in a Gene Pulser II (BioRad) at 0.240kV and 
0.950μFx1000.  After the procedure was finished, another 400μl of RPMI were added in the 
cuvette and all 800μl were added in a 6-well plate.  Fresh RPMI was added to a final volume of 
2ml.  Before any other treatment, transfectants were allowed to recover overnight in a humidified  
37°C/5%CO2 incubator.    
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2.9.2 Nucleofection 
Nucleofection was done for Jurkat cells to study apoptosis induction or CD95/CD95L expression 
after transfection because it is a more gentle procedure and results in less dead cells, an obvious 
advantage when studying cell death.  Generally the protocol provided by the manufacturer was 
followed, but every time before transfection the cells were checked for optimal conditions with as 
little death as possible and as higher transfection efficiency as possible.   For each nucleofection, 
5x106 cells were used.  The cell pellet was resuspended in 100μl of room temperature 
Nucleofector Solution and then either 5μg of plasmid DNA or 2μg of pmaxGFP (for transfection 
efficiency analysis) were added.  After mixing gently, the samples were poured in a cuvette 
provided by the manufacturer and after setting the correct program on the Nucleofector I device 
(Amaxa biosystems), nucleofection could take place.  The sample was then removed from the 
cuvette and was transferred in a culture plate containing 2ml of RPMI.  For establishing the 
successful production of transient transfectants which express the proteins of interest, Western 
blot analysis had to be carried out.  Because the protein of interest in a nuclear protein and 
nuclear extracts had to be made, a large number of cells was required.  For this reason, for each 
sample, 2-3 nucleofection reactions were pooled in 10ml of RPMI. All transfectants were allowed 
to recover overnight in a humidified 37°C/5%CO2 incubator.    
 
2.10 HiPerfect transfection (siRNA) 
 
For the introduction of siRNA in CEM cells, the HiPerfect system from Qiagen was used.  2x105 
cells were resuspended in 90μl of fresh RPMI with 9μl of HiPerfect transfection solution and the 
appropriate amount of siRNA.  Each sample was transferred in a well of a 96 well-plate and 
incubated for 6h in a humidified 37°C/5%CO2 incubator.  After incubation, the samples were 
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transferred in a 24 well-plate and 400μl of RPMI were added.  The cells were then further 
cultured in a humidified 37°C/5%CO2 incubator until efficient knock-down was achieved.  The 
efficiency of the procedure was checked with a negative control (siRNA Alexa Fluor 488) with 
target sequence AATTCTCCGAACGTGTCACGT (Qiagen), which provides green fluorescence 
when transfection is successful and the % of positively transfected cells was measured by flow 
cytometry after the pellets were resuspended in 200μl PBS.  Then the needed concentrations of 
the siRNA in question could be calculated.  Western blot analysis was used to determine the time 
point after siRNA introduction and the exact siRNA concentration that yielded the most efficient 
knock-down.  Because the number of the cells used for each transfection is low and Western blot 
with nuclear extracts requires more protein, 2-3 reactions were pooled after harvesting prior to 
analysis (Davies et al, 2004). 
 
 
2.11 Apoptosis assay 
 
2.11.1 Cell Stimulation 
Cells were stimulated with PMA and ionomycin.  End concentration of PMA was 10ng/μl and 
ionomycin 0.5μM.  Both substances were diluted from a stock of PMA 100ng/μl and ionomycin 
10mM.  For T cell stimulation, day 6 T cells were transferred into wells coated with 30 µg/ml 
anti-CD3 Ab (pb-anti-CD3) and were cultured for 24 h.   
 
2.11.2 Apoptosis detection 
For apoptosis analysis, cells were centrifuged at 2000rpm for 10mins, the cell pellet was washed 
once in 1xBPS and after another centrifugation the pellet was resuspended in 200μl of propidium 
iodide in Nicoletti buffer (50μg/ml) and the samples were incubated overnight at 4°C. The 
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following day staining was detected by flow cytometry (FCS canto) after gating on the cells at a 
forward- to side- scatter profile and look for staining positivity at PE-A.  Statistical analysis 
provided the percentage of fragmented nuclei out of the total of gated cells.  Specific apoptosis 
was calculated by the following formula: %specific apoptosis = [% dead cells-% dead cells 
(untreated control)] / [100-% dead cells (untreated control)] x100. 
 
2.12 Cell surface staining 
 
For the CD95 cell surface staining, 105 cells were used for each reaction.  All reactions were 
carried out at 4°C.  The cells were spun down and the pellet was washed with 500μl of freshly 
made PBS supplemented with 2% FSC.  The cells were then incubated for 15mins on ice with 
either the antibody of interest (human anti-APO-1) or isotype control antibody (IgG3, 
Pharmingen), diluted 1:100 in PBS/FSC.  After antibody incubation was finished, the cells were 
recovered by centrifugation at 2000rpm for 3mins and they were washed twice with PBS/FCS.  
Then 3μl of the secondary antibody were added in 100μl of PBS and the reactions were incubated 
for 20mins on ice in the dark.  Maintaining the reactions in the dark for as much as possible, the 
cells were washed three times in PBS/FCS and the final pellet was resuspended in 100μl of 
PBS/FCS to be analyzed by flow cytometry (Facs canto). 
 
2.13 Agarose gel electrophoresis 
 
All DNA products were separated using 0.7-2.5% (w/v) agarose in ½ x TBE buffer, according to 
the expected fragment size.  Separations were performed at a voltage ranging from 50-135V 
according to the concentration of the gel and the time duration was ranging from 20-40mins 
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according to the gel concentration and the expected fragment size.  Gels were visualized by UV 
illumination in a BioRad GelDocumentation system (BioRad life sciences). 
 
2.14 Quantitative real-time PCR 
 
For quantitative real-time PCR a PCR-Taqman Kit from Eurogentec was used.  A PCR mixture 
was prepared for each sample consisting of: 
PCR-Mix 
 
1.25μl PCR buffer (2x) 
2.50μl MgCl2 (10mM) 
1.00μl dNTPs (200μM) 
0.0625μl Hot Gold Star enzyme (0.05U)
0.125μl Uracil-N-glycosylase (0.02U) 
1.30μl H2O 
 
 
 
 
The different reactions carried out for quantitative real-time PCR were as follows and each 
sample yielded enough amount for triplicates of 25μl: 
CD95 Ligand 
 
0.88μl forward primer 
15.80μl reverse primer 
  3.50μl probe Taq 
  4.40μl cDNA template 
43.80μl  PCR mix 
20.30μl  H2O 
CD95 Receptor 
 
 5.30μl forward primer 
 5.30μl reverse primer 
 3.50μl probe Taq 
 4.40μl cDNA template 
43.80μl  PCR mix 
25.40μl  H2O 
β-actin 
 
  5.30μl forward primer 
15.80μl reverse primer 
  3.50μl probe Taq 
  4.40μl cDNA template 
43.80μl  PCR mix 
14.90μl  H2O 
 
 
 
 
 
 
The aliquots of 25μl were placed in a 96-optical well plate along with a triplicate of a control 
sample containing only water.  The reactions took place in a GeneAmp 5700 real-time PCR 
machine for 40-45 cycles and fold-increase in the mRNA levels of the gene in question was 
normalized with respect to β-actin levels for each sample.  
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2.15 Bioinformatics systems 
 
The WT1 mRNA sequence used for sequence comparisons was obtained from the NCBI 
nucleotide database for transcript variant D (http://www.ncbi.nlm.nih.gov).  Alignment of the 
sequenced clones against the known WT1 mRNA sequence was done with the ClustalW tool 
available at the European bioinformatics institute at http://www.ebi.ac.uk/. Translation of the 
sequenced clones was done by the Translate tool at the proteomics server ExPASy at 
http://www.expasy.org/.  Alignment of the translated sequence with the known WT1 amino acid 
sequence retrieved from the NCBI-protein database was done with the BLAST protein-protein 
alignment tool available at http://www.ncbi.nlm.nih.gov/BLAST/.   
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III Results 
 
1. WT1 expression in leukaemic T-cell lines 
 
1.1 Analyzing WT1 expression at the mRNA level 
As already mentioned, WT1 has been reported to be either overexpressed or mutated in both 
AML and ALL.  We therefore looked into whether WT1 is expressed in T-cell leukaemias. To 
characterize the expression patterns of WT1 in T-cell leukaemias seven leukaemic T-cell lines 
and primary T cells were investigated by RT-PCR with three different WT1-specific primers.  
For each set of primers, PCR conditions were initially optimized by carrying out a gradient 
PCR using mRNA from U2OS cells. The optimal conditions were then used to amplify the 
mRNA from the cell lines under investigation. To avoid mutations caused by the 
amplification procedure, a combination of proofreading polymerases was used to amplify the 
transcript from the leukaemic T-cell lines and primary T cells.  The region between 
nucleotides 784-1800 (end of transcript) was the region amplified using three different sets of 
primers (Fig.III.1A).  
 
The experiment showed that the mRNA corresponding to the C-terminus of WT1 was 
detected in most of the leukaemic cell lines studied, which is in accordance with a previous 
report (Inoue et al, 1994).  However, analysis of the N-terminus showed that not all of the 
leukaemias expressed full length WT1 transcript.  Only Hut78 and CEM expressed full length 
WT1.  Molt4 did not express exons 1-3 and Jurkat did not express exons 1-6.  Myla, SeAx 
and HH did not express WT1 at all (Fig.III.1B).  Healthy, mature resting T cells or T cells 
stimulated with either anti-CD3 or PMA and ionomycin did not produce WT1 (Fig.III.1C). 
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Figure III.1. WT1 mRNA expression analysis in leukaemic T-cell lines.   
(A) Diagrammatic representation of the WT1 transcript indicating the major splicing sites and 
the exons encoding the four zinc-fingers.  Labelled arrows A-C show the position of the three 
different sets of primers used to amplify the mRNA in RT-PCR. (B) RT-PCR on total mRNA 
from the indicated leukaemic cell lines either induced with PMA and ionomycin or non-
induced, using WT1 specific primers. The two bands appearing in lines B and C contain the 
equivalent splicing isoforms. (C) RT-PCR on total mRNA from primary T cells either non-
induced (lane 1) or induced with anti-CD3 (lane 2) or PMA and ionomycin (lane 3) with 
WT1-specific primer set C.  U2OS mRNA is shown for positive control.  For loading control 
β-actin is shown. 
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Within this work it was not possible to amplify nucleotides 1-783 of exon 1 although several 
sets of published primers (also at the genomic level) were used (Makrigiannakis et al, 2001; 
Schumacher et al, 2003; Oji et al, 2004).  Interestingly none of these researchers has been 
able to provide an optimized PCR product for exon 1. This was due to the high GC content of 
the transcript, which impeded optimized amplification.  
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1.2 WT1 mutation screening 
The WT1 cDNAs produced by RT-PCR, with the three sets of primers, were cloned and 
sequenced.  From each cloning experiment, approximately 24 samples were randomly 
selected and screened for presence of insert.  After positive clone selection, between five and 
ten different positive clones were randomly selected from each experiment and sent for 
sequencing (SeqLab).  To screen for mutations in the WT1 transcript, the sequences obtained 
were then aligned against the known WT1 transcript sequence (NCBI, WT1 variant D, which 
contains both exon 5 and KTS splicing sequences) in a ClustalW alignment (EBI) (Fig.III.2).  
The alignment results indicated that the mRNA sequences amplified had no mutations.  Only 
in the C-terminal part of the gene, a single nucleotide difference was seen (Fig.III.2C), G in 
cDNA at position 1525 compared to A in the published genomic DNA sequence (NCBI).  
However, this difference had no effect on the protein, since translation of the amplified cDNA 
sequence (ExPasy) and alignment with the known WT1 amino acid sequence gave 100% 
match (Fig.III.2D).   
 
Sequencing of exons 2-6 at the N-terminal part of the gene showed that the sequences for both 
exon 5 splice variants were obtained in a ratio of 1:2.3 for WT1-Exon5:WT1+Exon5.  
Moreover, for the C-terminal part of the gene, both WT1-KTS and WT1+KTS sequences 
were obtained at an equal proportion.  All positive clones (5-10) that were sequenced from 
each experiment produced the same sequencing result.  The above results showed that the 
leukaemic cell lines CEM and Hut78 expressed full-length wild-type WT1 transcript, whereas 
mature healthy resting or activated T cells and the leukaemic cell lines, Myla, SeAx and HH 
did not produce WT1 transcript at all. Contrary to previous reports, the leukaemic cell lines 
Jurkat16, Jurkat282 and Molt4 (Inoue et al, 1994) did not produce full-length WT1 transcript 
(Fig.III.3).   
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Figure III.2. Mutation screening in the WT1 transcript.  Representative ClustalW 
alignment (EBI) of the cloned and sequenced WT1 transcripts against the known WT1 mRNA 
sequence for the WT1 (+/+) variant (NCBI).  (A) Alignment of exons 1-3, (B) alignment of 
exons 2-6 and (C) alignment of exons 6-10.  The blue rectangle points a position where a G 
always appears in the cDNA but an A has been given to the genomic sequence (NCBI). (D) 
BLAST alignment (NCBI) of the translated C-terminal cloned sequence against the WT1 
protein amino acid sequence until the translation stop (STP) codon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) 
B) 
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Figure III.3. Summary of WT1 expression pattern.  The top diagram shows the amplified 
WT1 transcript (highlighted in blue). At the bottom, the overall length of the transcript that 
was amplified by RT-PCR in the indicated leukaemic cell lines and in primary T cells is 
shown in blue lines.  Dotted lines represent absence of transcript. 
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1.3 Analyzing WT1 expression at the protein level  
The finding that some leukaemic cell lines produce WT1 transcript does not imply that they 
necessarily produce WT1 protein. To further investigate whether WT1 mRNA expression 
corresponds to the WT1 protein expression in these cell lines, Western blot analysis for WT1 
protein was carried out.  Two different antibodies were used, one directed against the C-
terminus of the protein (C19) and one against the N-terminus of the protein (F6). In 
accordance to the mRNA analysis, the full length WT1 was detected only in Hut78 and CEM 
cells (Fig.III.4).  As mentioned above, one of the special characteristics of WT1 is its ability 
to produce many splice variants. The WT1 transcripts previously amplified by RT-PCR in the 
leukaemic cell lines Jurkat and Molt4 could be translated into truncated protein products 
whose functions are not known yet.  However, in the Jurkat cell lines no full-length protein 
products were detected.  This does not exclude the existence of very low molecular weight 
proteins which were non-detectable with the antibodies used.  Moreover, in the leukaemic cell 
line Molt4, not all the transcript was detectable at the mRNA level.  The C-terminus but not 
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the complete N-terminus could be amplified.  Consistent with this result, at the protein level, 
WT1 was recognized with the antibody directed against the C-terminus. However, the 
antibody that recognizes the first 180 amino acids of the protein (F6) did not detect any 
protein product.  This data demonstrates that not all T-cell lines, which have been reported to 
overexpress WT1, such as Jurkat and Molt4 (Inoue et al, 1994; Inoue et al, 1997), actually 
produce WT1 protein. 
 
Figure III.4. WT1 protein expression in T-cell leukaemias.  Western blot analysis of 
nuclear extracts from the indicated cell lines either without treatment (A) or after 24h of PMA 
and ionomycin stimulation (B) using two different WT1 specific antibodies, F6 directed 
against the N-terminus and C19 against the C-terminus as shown on the diagram on the top.  
The two bands indicate the exon5 splicing isoforms.  U2OS was used as a positive control. 
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2. WT1 is involved in AICD 
 
2.1 WT1 expression coincides with higher AICD 
One of the goals of this study was to understand the role WT1 plays in the apoptosis of T 
cells. For this reason, all leukaemic T-cell lines were analyzed for apoptosis upon PMA and 
ionomycin stimulation, which mimics TCR stimulation.  All the cell lines were either left 
untreated or were treated with PMA and ionomycin for 24h.  Then they were stained with 
propidium iodide and DNA fragmentation was analyzed by flow cytometry the following day.  
After 24h of stimulation with PMA and ionomycin high levels of apoptosis were seen for the 
WT1-expressing cell lines Hut78 and CEM (Fig.III.5). To determine whether the elevated 
apoptosis detected in Hut78 and CEM (24h after stimulation) was mediated by the CD95 
system, an antibody against the CD95L (anti-FasL) was used to inhibit the effect of 
CD95/CD95L-mediated apoptosis.  The apoptosis in Hut78 and CEM induced by PMA and 
ionomycin was completely blocked in the presence of the antibody against CD95L (Fig.III.6A 
and B). These experiments indicate that WT1 might play an important role in CD95-mediated 
AICD in T cells. 
 
Figure III.5. Apoptosis in leukaemic T-cell lines correlates with WT1 expression.  
Leukaemic T-cell lines were induced with PMA and ionomycin for 24h before flow 
cytometry analysis of propidium iodide staining for DNA fragmentation.  Non-induced T-cell 
lines were used as controls. One representative of five experiment is shown. 
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Figure III.6.  Apoptosis of WT1-expressing leukaemias upon TCR stimulation is 
CD95L-dependent.  (A) CEM apoptosis and (B) Hut78 apoptosis could efficiently be 
blocked with anti-CD95L antibody.  Cells were either left untreated (open bars) or were 
stimulated with PMA and ionomycin for 24h (coloured bars).  Antibody against the CD95L 
(anti-CD95L) (pink bars) and an isotype IgG1 antibody (grey bars) were added 30mins before 
PMA and ionomycin treatment. 
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2.2 Ectopic expression of WT1 in WT1-non-expressing T-cell leukaemia enhances 
AICD 
To further analyze the actual role of WT1 in AICD of T-cell leukaemias, two different 
approaches were followed. In the first approach, WT1 was introduced into J16 cells, which do 
not express WT1, to examine if WT1 would enhance apoptosis. In the second approach, the 
WT1 gene was silenced by WT1 siRNA in CEM cells that express WT1, to see whether 
knocking down WT1 would lead to a reduction in AICD.   
 
For the first approach, J16 cells had to be transfected and then apoptosis would be analyzed.  
J16 cells, however, are very difficult to transfect and very sensitive to such treatments.  
Therefore, careful analysis for transfection methods was necessary and nucleofection by 
Amaxa proved to be one of the best.  Still, optimization had to be carried out before each 
experiment to ensure high transfection efficiency (50-80%) with as low background cell death 
as possible (Fig.III.7). 
PMA/Iono - + + + PMA/Iono - + + + 
Anti-CD95L - - + - 
IgG1 - - - + 
Anti-CD95L - - + - 
IgG1 - - - + 
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Figure III.7. Optimized transfection conditions for J16 cells.  Jurkat 16 cells were 
transfected with a GFP-expressing construct and analyzed for cell death after transfection by 
flow cytometry.  The living cells were gated (left panel, shown in red) and percent 
fluorescence was calculated on the gated living cells (right panel).  A >50-80% fluorescence 
was used for further experiments. 
 
 
58.2%  
 
 
 
 
 
Once nucleofection conditions were optimal, J16 cells were transiently transfected with empty 
vector pCMV or WT1+KTS or WT1-KTS.  After overnight recovering, the cells were either 
left untreated or were stimulated with PMA and ionomycin and apoptotic cell death was 
measured 24h after stimulation by flow cytometry.  Stimulated cells transfected with WT1-
KTS were also treated with an antibody against the CD95L or isotype control antibody.  The 
expression of WT1-KTS in J16 cells resulted in more than a 3-fold increase in the AICD 
levels, whereas WT1+KTS had no effect. Blocking with the antibody against the CD95L 
confirmed that the apoptosis induced was CD95L-mediated (Fig.III.8A).  Calculation of the 
percentage of specific apoptosis showed that WT1-KTS brought about a 5-fold increase when 
compared to empty vector or to WT1+KTS (Fig.III.8B). In addition, Western blot analysis of 
nuclear extracts from the transfectants confirmed successful expression of both variants 
indicating that the effect seen was not due to unequal expression but was the result of the 
WT1-KTS action (Fig.III.8C).   
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Figure III.8. Ectopic expression of WT1-KTS increases AICD in Jurkat leukaemia.   
(A) J16 cells were transfected with empty vector CMV, WT1+KTS or WT1-KTS and then 
either left untreated (open bars) or stimulated with PMA/ionomycin for 24h (coloured bars).  
The stimulated cells were also treated with anti-CD95L or isotype control. % DNA 
fragmentation was analyzed by flow cytometry for propidium iodide positive cell staining. (B) 
% Specific apoptosis of J16 cells transfected with either empty vector CMV, WT1-KTS or  
0
5
10
15
20
WT1+KTS. (C) Western blot analysis with WT1-C19 antibody on nuclear extracts from the 
transfectants showing that both WT1 constructs are expressed in J16 cells after transfection.  
CEM nuclear extract is shown for positive control and YY1 for loading control. One of three 
experiments is shown. 
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2.3 Silencing of WT1 in WT1-expressing T-cell leukaemia reduces AICD 
In the second approach, to verify that WT1 is an important player in AICD of CEM cells, 
WT1 had to be silenced.  CEM cells constitute another sensitive cell line that requires gentle 
handling and successful transfection without massive death is almost inevitable.  Several 
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transfection methods for the introduction of the siRNA were tested but the HiPerfect system 
(Qiagen) proved to be the only system that allowed efficient knock-down avoiding cell death 
due to the procedure itself.  The efficiency of the transfection was determined by introducing 
different concentrations of fluorescent oligonucleotides and analyzing the transfectants 24h 
later by flow cytometry.  Non-transfected cells or cells transfected with buffer alone did not 
produce any fluorescence (Fig.III.9A). Addition of increasing amounts of fluorescent 
oligonucleotides resulted in a dose-dependent increase in fluorescence.  Furthermore, the aim 
of this experiment was to look for the apoptotic pattern of CEM cells after stimulation when 
WT1 is knocked-down.  Therefore, it was necessary to certify that any effects seen would not 
be due to the siRNA introduction procedure.  For this reason, CEM cells were either not-
transfected, control-transfected with scrambled oligonucleotides or transfected with increasing 
concentrations of WT1-siRNA. Apoptosis was assayed 24h post-transfection, when no 
decrease in the WT1 levels could be detected thus far (Fig.III.9B).  The transfection procedure 
resulted in an increase in apoptosis which was unaffected by the addition of increasing 
concentrations of siRNA.  These results suggest that the procedure indeed sensitized CEM 
cells, an event that could not be avoided, but it also shows that the oligonucleotide against 
WT1 did not lead to an increase nor did it lead to a decrease in apoptosis.  Therefore any 
effects seen after the knock-down of WT1 are expected to be entirely due to the absence of 
WT1. 
 
Once the silencing transfection system was optimized, the siRNA against WT1 was introduced 
into CEM cells.  After 48 hrs of recovering, the cells were stimulated with PMA and 
ionomycin. Activation induced apoptotic cell death was measured 24 hrs after stimulation and 
the WT1 expression levels were controlled by Western blot.  The introduction of scrambled 
oligonucleotides in CEM cells had no effect in WT1 expression whereas the WT1-siRNA 
resulted in the down-regulation of WT1 expression in a dose dependent manner (Fig.III.10A). 
 55
K.Bourkoula  III Results 
Since best down-regulation of WT1 expression was achieved with siRNA concentrations of 
120 and 180nM, these were used in the subsequent experiments, which showed that AICD 
was suppressed by the WT1-siRNA in a dose-dependent manner (Fig.III.10B).  Moreover, the 
negative values obtained for the specific apoptosis assay of CEM cell transfected with 180nM 
of WT1-siRNA indicated that not only apoptosis induction was refrained, but that there was 
also proliferation. These results further confirm an important role of WT1 in AICD of T cells. 
 
Figure III.9.  Establishing the WT1-specific siRNA system. (A) CEM cells were either not 
transfected (-), mock transfected (buffer) or transfected with increasing concentrations of 
green fluorescent oligonucleotide for 24h and fluorescence was detected with flow cytometry.  
(B) CEM cells were either not transfected (-), mock transfected (buffer) or transfected with 
the indicated increasing concentrations of WT1-siRNA. 24h post-transfection specific 
apoptosis was assayed by flow cytometry for nuclei fragmentation. 
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Figure III.10. WT1 specific siRNA decreases AICD in CEM leukaemia.  (A) Western blot 
analysis with WT1-C19 antibody of nuclear extracts from CEM cells either control 
transfected with scrambled oligonucleotide (-) or transfected with the indicated increasing 
amounts of WT1 specific siRNA. Transcription factor YY1 was used as a loading control. (B) 
Specific apoptosis was assayed 24h after PMA and ionomycin stimulation of CEM cells 
transfected for 48h with different amounts of WT1 specific siRNA or scrambled 
oligonucleotides for control.   The experiment shown is representative of five. 
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3. WT1 is involved in CD95L expression 
 
3.1 WT1 expression coincides with higher CD95L expression 
WT1 is a zinc-finger transcription factor with target sequences similar to Egr1 (Lee & Haber, 
2001). As it has been previously shown that Egr1 binds and up-regulates the CD95L promoter 
after T cell stimulation (Li-Weber et al, 1999) and that the apoptosis seen in WT1-expressing 
T-cell leukaemias is CD95L-mediated (Fig.III.11), it was of interest to see whether WT1 
plays a role in the regulation of the CD95L gene expression.  To investigate this, the CD95L 
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mRNA expression levels were analyzed by reverse-transcriptase PCR and quantitative real-
time PCR in all the leukaemic cell lines.  The results showed higher basal expression levels of 
CD95L mRNA in the WT1-expressing cell lines Hut78 and CEM when compared with the 
WT1-non-expressing cell lines.  The CD95L mRNA expression levels were further up-
regulated upon PMA and ionomycin stimulation in all cell lines, but the increase in the WT1-
expressing cell lines Hut78 (4-fold) and CEM (5-fold) was notably stronger than in the WT1-
non-expressing cell lines (Fig.III.11). This data indicates that WT1 may promote the 
expression of CD95L at the transcriptional level.  
 
 
Figure III.11. WT1 expression coincides with higher CD95L expression.   
(A) Amplification by RT-PCR of the CD95L cDNA for the different leukaemias either 
without stimulation (-) or induced for 1.5h with PMA and ionomycin (+). (B) Respective 
quantitative real-time PCR analysis of the CD95L for the different leukaemias either without 
stimulation or induced for 1.5h with PMA and ionomycin. 
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3.2 WT1 expression does not correlate with CD95 expression 
To verify that the apoptosis induction was due to CD95L up-regulation and was not 
dependent on increased levels of CD95, CD95 mRNA levels were examined with reverse 
transcriptase PCR.  This experiment showed that CD95 levels remained almost unchanged 
among the different cell lines (Fig.III.12A). Quantitative real-time PCR was then carried out 
in order to obtain more detailed expression levels, since small changes would not have been 
clearly detected by a non-quantitative method.  The quantitative real-time PCR showed that 
the receptor’s mRNA levels varied between non-stimulated and stimulated conditions, but the 
overall differences in expression did not correlate with WT1 expression (Fig.III.12B).  For 
example, in both  J16 and CEM, CD95 levels were increased after stimulation, but only CEM 
was shown to express WT1. Since mRNA levels 1h30mins after stimulation did not 
necessarily reflect the amount of receptor expressed on the surface when apoptosis was 
examined, CD95 protein levels present on the surface of the cells were analyzed. Therefore, 
cell surface staining for CD95 was carried out in all cell lines 24h after stimulation.  The 
CD95 levels on the surface of the leukaemic cell lines studied were very high and remained 
high after induction with PMA and ionomycin irrespective of WT1 expression (Fig.III.12C).  
These results suggest that WT1 did not have an effect on CD95 and the increase in the 
apoptosis levels upon PMA and ionomycin stimulation in the WT1-expressing cell lines, 
hence depends on CD95L expression. 
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Figure III.12. WT1 expression does not correlate with CD95 expression.   
(A) Amplification by RT-PCR of the CD95 cDNA for the different leukaemic cell lines either 
without stimulation (-) or induced for 1.5h with PMA and ionomycin (+). (B) Quantitative 
real-time PCR analysis of CD95 for the different leukaemias either without stimulation or 
induced for 1.5h with PMA and ionomycin and (C) All the cell lines either non-treated or 
induced overnight with PMA and ionomycin were stained for cell surface CD95 with a CD95-
specific antibody (anti-APO) and staining was detected by flow cytometry.  Non-stained cells 
and isotype controls are shown.    
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3.3 Ectopic expression of WT1 in a WT1-non-expressing T-cell leukaemia enhances 
CD95L mRNA expression 
In order to gain a deeper insight in the relation between WT1 and CD95L expression, WT1 
was introduced into the WT1-non-expressing Jurkat T cells by transient transfections. Two 
WT1 expressing plasmids, one encoding the variant form of WT1 with high DNA-binding-
affinity (WT1-KTS) and one encoding the variant form of WT1 with low DNA-binding-
affinity (WT1+KTS), were used to transfect J16 cells and the CD95L expression levels were 
then analyzed by quantitative real-time PCR.  Ectopic expression of the WT1-KTS variant 
resulted in a 9-fold increase in CD95L mRNA expression, whereas only a 2-fold increase in 
the CD95L mRNA was seen in the WT1+KTS transfected cells (Fig.III.13A).   The different 
effects of the two plasmids in the CD95L mRNA expression were not due to unequal 
expression in the transfected cells, since both WT1 variants were equally expressed 24h post-
transfection (Fig.III.13B). These results indicate that WT1 may enhance the CD95L mRNA 
expression. 
 
Figure III.13. Ectopic expression of WT1-KTS upregulates the CD95L.  (A) Quantitative 
real-time PCR of CD95L and CD95 after transient transfection of J16 cells with WT1+KTS, 
WT1-KTS or empty vector CMV.  The experiment shown is one of three reproducible ones. 
(B) Western blot analysis of whole cell lysates from the transfected cells using the anti-WT1 
C19 antibody to detect the expression of WT1 protein 24h post-transfection.  The two bands 
appearing in the control empty vector pCMV transfection are due to unspecific binding of the 
polyclonal antibody used on whole cell lysates.       
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3.4 Silencing of WT1 in WT1-expressing T-cell leukaemia reduces CD95L mRNA 
expression 
In order to study the effect of WT1 silencing on CD95L expression, CEM cells were left 
untreated or were transfected with either scrambled oligonucleotides or with WT1-siRNA.  
After an incubation of 70h to allow silencing to take place, the cells were stimulated with 
PMA and ionomycin for 1h30mins and total mRNA was extracted.  The mRNA was then 
reverse-transcribed and the cDNA was used for quantitative real-time PCR of the CD95L. 
The introduction of WT1-specific siRNA, resulted in a drop of CD95L expression levels in a 
dose-dependent manner (Fig.III.14).  Addition of scrambled oligonucleotides did not alter 
CD95L expression compared to untreated CEM control cells. 
 
Figure III.14. Silencing of WT1 decreases expression of CD95L mRNA. Real-time PCR 
for CD95L mRNA expression 70h after transfection of CEM cells with either scrambled 
oligonucleotides or the indicated concentrations of WT1-specific siRNA and 1.5h of PMA and 
ionomycin stimulation. 
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4. WT1 activates the CD95L promoter  
 
   4.1 Ectopic expression of WT1 increases CD95L promoter activity 
The most putative way that WT1 could affect CD95L transcription would be by directly 
acting on its promoter through the Egr1 binding sites and hence altering its transcriptional 
levels.  To examine whether WT1 enhances CD95L expression at the transcriptional level, 
J16 cells were co-transfected with a CD95L promoter-luciferase construct (wt) (Fig.III.15) 
together with either the WT1+KTS or the WT1-KTS plasmid construct. Analysis of the 
luciferase production showed that both WT1 constructs enhanced the CD95L promoter 
activity. The effect was higher when the WT1-KTS expression plasmid was co-transfected 
(Fig.III.16). To confirm that WT1 enhances promoter activity through the Egr-binding sites, a 
CD95L promoter-luciferase construct where all three Egr binding sites were mutated (Egr-
mut) was included in the same setting. The data obtained showed that mutations at the Egr 
sites significantly diminished the effects of WT1 on the CD95L promoter (Fig.III.16).   
 
Figure III.15.  Egr1 binding sites on the CD95L promoter.  Schematic representation of 
the composite Egr1/NF-AT binding sites on the CD95L promoter relative to the transcription 
start site (top) and respective DNA binding sequences of Egr1 (highlighted in pink) and NF-
AT (highlighted in blue) used in luciferase reporter constructs and for which oligonucleotides 
were designed (bottom). 
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Figure III.16.  WT1 expression increases CD95L promoter activity.  Luciferase activity of 
the CD95L promoter after co-transfection of J16 cells with either a wild-type CD95L 
promoter-luciferase construct or an Egr1-mutated CD95L promoter-luciferase construct in 
combination with WT1+KTS, WT1-KTS or empty vector as control (-).  Cells were either 
non-induced or induced for 8h with PMA and ionomycin. 
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4.2 WT1-KTS driven CD95L promoter activity occurs through Egr1 sites 
To further verify that the CD95L Egr sites could confer the WT1-mediated transcriptional 
activation, co-transfection experiments in J16 cells were performed using luciferase reporter 
plasmids containing 3 copies of each Egr binding site.  Each luciferase construct was 
transfected along with the WT1+KTS, the WT1-KTS plasmid or an empty vector as a control.  
In all experiments, the WT1+KTS had no effect on CD95L induction, which was similar to 
the empty vector.  The WT1-KTS however, induced high luciferase production from all 
binding sites (Fig.III.17A). This effect was specific to the Egr binding sites, since WT1-KTS 
did not have any effect on a luciferase reporter construct containing 5 copies of the Sp1 
binding site (Fig.III.17B).   
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Figure III.17. WT1-KTS  driven CD95L promoter activity occurs through Egr1 sites.  
(A) J16 cells were co-transfected with a CD95L promoter-luciferase construct (containing 
three copies of either the -120, the -180 or the -680 Egr1 sites) and WT1+KTS, WT1-KTS or 
empty vector CMV.  (B) Co-transfection of J16 cells with a CD95L promoter-luciferase 
construct containing five copies of the Sp1 binding site along with either WT1+KTS, WT1-
KTS or empty vector CMV. 
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To further confirm that the CD95L Egr sites could confer the WT1-mediated transcriptional 
activation during AICD, the same co-transfection experiments were performed using 
luciferase reporter plasmids containing 3 copies of each Egr binding site, but the cells were 
also stimulated with PMA and ionomycin for 24h (Fig.III.18).  As it was seen, WT1+KTS 
had no effect on the CD95L promoter after stimulation since the levels of luciferase 
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production were similar to the background activation levels of the promoter, which occured 
with empty vector  CMV on all three Egr1 binding sites.  On the contrary, all three Egr1 
binding sites were responsive to WT1-KTS with a higher effect detected at the -120 and -180 
sites (Fig.III.18).  This data further supports WT1-KTS action on the CD95L promoter 
through the Egr1 binding sites.      
 
Figure III.18. WT1-KTS driven CD95L promoter activity occurs through Egr1 sites 
after T cell activation. J16 cells were co-transfected with a CD95L promoter-luciferase 
construct containing three copies of either the -120, the -180 or the -680 Egr1 sites along with 
a plasmid expression construct of either WT1+KTS (grey bars) or WT1-KTS (blue bars) or 
with empty vector CMV (empty bars) for control.  The transfectants were either left untreated 
(-) or were stimulated with PMA and ionomycin for 24h (+). 
 
   
 
 
 
 
 
 
 
 
 
 
 
5. WT1 binds directly on the CD95L promoter  
 
5.1 Recombinant WT1-KTS binds on the CD95L promoter 
To further investigate whether WT1 directly binds to the CD95L Egr sites, recombinant 
WT1+KTS and WT1-KTS proteins were analyzed for their ability to associate with 
oligonucleotides encoding each of the three Egr binding sites (Fig.III.15) by an 
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electrophoretic mobility shift assay (EMSA) (Fig.III.19).  All three sites showed binding of 
the WT1-KTS but not of the WT1+KTS.  In agreement with the luciferase reporter results, the 
strongest binding was shown at the -120 site. This data demonstrates that WT1 enhances 
CD95L transcription by directly interacting with at least one of the Egr binding sites of the 
CD95L promoter.       
 
Figure III.19. WT1-KTS can bind on the CD95L promoter.   
Recombinant WT1+KTS or WT1-KTS proteins were used to probe oligonucleotides 
representing the three Egr1 binding sites on the CD95L promoter at an electrophoretic 
mobility shift assay. 
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5.2 WT1 binds on the CD95L promoter at -120 in WT1-expressing T-cell 
leukaemia 
As WT1 has already been shown to be expressed in CEM leukaemia (Fig.III.1& 4) and to 
bind directly to the CD95L promoter (Fig.III.19), it was of importance to check whether WT1 
was also able to bind on the CD95L promoter in CEM.  For this reason, nuclear proteins from 
CEM cells either stimulated with PMA and ionomycin for 3h or left untreated, were analyzed 
for their ability to interact with oligonucleotides representing the Egr binding sites on  the 
CD95L promoter by EMSA.  The EMSA carried out with oligonucleotide probes representing 
the –120 site, clearly showed, that after stimulation differential banding patterns appear, with 
two new protein complexes being prominently formed on that site of the promoter 
(Fig.III.20).  To define whether the nuclear proteins of interest were part of these complexes, 
a supershift assay was carried out, in the presence of antibodies against Egr1 and WT1.  With 
the antibody against Egr1 the bottom complex was shifted such that it disappeared completely 
and the top complex was highly reduced.  Therefore, after stimulation Egr1 was involved in 
the formation of at least two complexes at -120 on the CD95L promoter.  In addition, in the 
presence of the antibody against WT1, it was seen that both bands were again reduced in their 
intensity, indicating that WT1 was also involved in the formation of these complexes at -120 
(Fig.III.20).  However, the addition of an antibody against Sp1 had no effect in band shifting 
or intensity, highlighting binding specificity for Egr1 and WT1 at -120 on the CD95L 
promoter. 
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Figure III.20. WT1-KTS binds on the CD95L promoter at -120 in WT1-expressing-
CEM leukaemia.   Oligonucleotide probes representing the -120 Egr1 binding site on the 
CD95L promoter were used to detect binding of nuclear proteins from CEM cells either 
without stimulation (-) or after 3h of PMA and ionomycin stimulation (+).  Egr1 and WT1-F6 
antibodies were used for supershift assay.  Sp1 antibody controls the supershift reaction and 
NF-Y is shown for loading control.  New prominent complex formation after stimulation is 
indicated by blue clammer and the position of the WT1-binding complex by red clammer. 
Stars depict non-specific complexes.  Shown, is one experiment representative of three 
reproducible ones. 
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IV Discussion 
 
The role of WT1 in leukaemogenesis has been very controversial.  Several studies have 
shown that it is mutated in leukaemias (King-Underwood et al, 1996; King-Underwood & 
Pritchard-Jones, 1998), whereas others have indicated that it is overexpressed (Inoue et al, 
1997; Menssen et al, 1995).  These discrepancies have resulted in two different opinions on 
WT1’s role in leukaemogenesis.  On one hand it is thought that it is a tumor suppressor, and 
on the other hand it is thought that it acts as a tumor survival factor.  It is likely that WT1 can 
be attributed both characteristics depending on the cell context, its expression pattern and 
mutation status during development.  In combination, these factors can eventually lead to 
contradictory but understandable effects (Fig.IV.1).   
 
Figure IV.1. Schematic representation of the differential effects of WT1 on 
leukaemogenesis.  WT1 is expressed during the early stages of haematopoiesis (red line).  If 
its expression is lost prematurely or if loss of function mutations occur, then this can lead to 
leukaemia and gives WT1 a tumor suppressor function (blue pathway).  If however, its 
expression continues after the normal stages (red dotted line) or a dominant-negative mutant 
protein is produced then this can also lead to leukaemia (red pathway) giving however WT1 a 
tumor promoter function.    
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It is known that WT1 expression is restricted during the early stages of haematopoiesis 
(Maurer et al, 1997).  Also, it is suggested that WT1 is involved in apoptosis induction by 
upregulating the pro-apoptotic protein Bak (Morrison et al, 2005) and in apoptosis inhibition 
by upregulating the anti-apoptotic Bcl-2 (Mayo et al, 1998).  Bearing this in mind, two 
different scenarios can be explained.  In the first case, if WT1 is mutated (loss of function 
mutations) at an early stage during haematopoiesis ‘when its expression might be essential for 
apoptosis induction (e.g., negative selection)’ this would lead to leukaemia, and hence WT1 
could be characterized as a tumor suppressor.  In the second case, if expression of  WT1 
continues after the appropriate time, this would probably affect the proliferation status of the 
WT1-expressing cells, giving them a growth advantage (through Bcl-2 upregulation) and 
hence promoting tumor growth.  In addition, if a mutation which gives rise to a dominant-
negative effect occurs at early stages of development, then this would also have a tumor 
growth promoter function.   
 
However, WT1’s role in T cell leukaemogenesis and T cell apoptosis is not well studied. 
Therefore, it was of interest to study its expression patterns and mutation status in T cell 
leukaemias and characterize its involvement in CD95/CD95L-mediated apoptosis. Because 
WT1 is not expressed in mature T cells the study was initiated in leukaemic T-cell lines, of 
which some were already reported to overexpress WT1.   
 
 
1. WT1 expression analysis in leukaemic T-cell lines 
 
In this analysis, eight leukaemic T-cell lines were used, namely CEM, Hut78, Molt4, Myla, 
SeAx, HH and two Jurkat sub-clones, Jurkat 16 and Jurkat 282.  The expression patterns of 
WT1 were analyzed both at the mRNA and at the protein level.  At the mRNA level, RT-PCR 
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reactions which amplified the WT1 transcript from nucleotide 784 (exon1) to nucleotide 1800 
(end of transcript) were carried out.  The RT-PCR showed that only CEM and Hut78 express 
full-length WT1 transcript.  Jurkat 16, Jurkat 282 and Molt4 express part of the transcript (C-
terminal part) and Myla, SeAx and HH do not express WT1 at all (Fig.III.1).  Cloning and 
sequencing of the amplified regions showed that all parts of the transcript expressed were 
wild-type and no mutations could be identified (Fig.III.2).   
 
Because mRNA expression does not necessarily imply protein expression, to confirm WT1 
expression, Western blot analysis for the WT1 protein was carried out (Fig.III.4).  WT1 
protein could not be detected at all in the cell lines Jurkat 16 and Jurkat 282, in Myla, SeAx 
and HH.  The finding that Jurkat cells do not produce WT1 is contradictory to a previous 
report, whereby RT-PCR alone on the C-terminus of the transcript suggested that Jurkat cells 
overexpress WT1 (Inoue et al, 1997).  It is possible, however, that in Jurkat where C-terminal 
transcript is detected, that a truncated WT1 protein is produced, but was not detected in this 
piece of work.  Further investigation of this was beyond the scope of this study as the aim was 
to screen for the presence or absence of wild-type WT1 expression and these results indicate 
that Jurkat cells do not produce wild-type WT1 protein.  
 
Moreover, in the cell line Molt4, the N-terminus of the transcript (exons 1-3) was not 
detected.  The protein analysis showed a WT1 protein that could be detected with the 
antibody against the C-terminus but not with the antibody against the N-terminus (which 
detects the first 180 amino acids of the protein).  It is questionable whether this is indeed a 
WT1 protein product, as the C-terminal antibody is polyclonal and sometimes detects some 
protein at the same molecular weight of WT1, even in the cell lines that do not express WT1 
at all, e.g., SeAx and HH.  This is one of the reasons the antibody against the N-terminus was 
used.  It can be seen that with this antibody, no actual WT1 protein is detected in Molt4.  The 
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finding that Molt4 does not produce WT1 disagrees with the previous report in which only an 
RT-PCR against the C-terminus of the transcript was performed.  In that study, it was 
therefore mistakenly suggested that WT1 is overexpressed in Molt4 (Inoue et al, 1997).  
Collectively, the RT-PCR and the Western blot analysis results in my work supported the 
conclusion that wild-type WT1 is expressed only in the leukaemic cell lines CEM and Hut78.  
This analysis of WT1 expression is by now one of the most representative, as previous 
research was based mainly on reverse-transcriptase PCR done only on the C-terminal part of 
the transcript (exons 6-10), and in most cases no protein analysis was ever done.   
 
The above findings highlight the importance of a more careful WT1 expression analysis 
before making any conclusions on its overexpression status in leukaemias.  WT1 is lately 
considered as a good target for immunotherapy based on its expression or overexpression 
(Inoue et al, 1994; Gao et al, 2000).  As shown above, leukaemic T-cell lines previously 
thought to overexpress WT1 actually do not produce WT1 at all.  Therefore, expression of 
WT1 should not be carried out solely through  reverse-transcriptase PCR on the C-terminus of 
the transcript, even if it is difficult to amplify the N-terminus.  Additionally, protein analysis 
or staining for WT1 should be implemented.  Otherwise, the results of WT1-targeted 
immunotherapy may prove to be detrimental. 
 
 
 
2. WT1 is involved in AICD 
 
After having identified the leukaemic cell lines that actually produce WT1, a comparison of 
the apoptotic behaviour of these cell lines upon T cell receptor stimulation was feasible.  
Without any stimulation, the apoptosis levels of the leukaemic cell lines were very low. All 
the cell lines responded to the apoptosis induction, however, the Hut78 and CEM reaction to 
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stimulation was distinguishably more prominent (Fig.III.5). The apoptosis levels after PMA 
and ionomycin treatment in Hut78 and in CEM showed a more than 2-fold increase, when 
compared to a less than 1-fold increase in the other cell lines.  This result is intriguing, as full-
length WT1 was only detected in Hut78 and CEM. 
 
In order to verify that the apoptosis detected in Hut78 and CEM was mediated by the 
CD95/CD95L system, the CD95L was blocked with an antibody (Fig.III.6).  Indeed, blockage 
of the CD95L action, recovered survival in these cell lines, as the apoptosis levels under PMA 
and ionomycin treatment dropped down to background apoptosis levels.  The above data for 
the first time indicates that WT1 expression in the leukaemic cell lines coincides with higher 
apoptotic cell death. 
 
To confirm that the enhanced AICD is influenced by the presence of WT1, two different 
systems were designed.  In the first system, WT1 was transfected into a WT1-non-expressing 
cell line with low apoptotic death after 24h of stimulation.  As such, Jurkat cells provided a 
good system and WT1-KTS or WT1+KTS was ectopically expressed in either non-treated 
cells or in cells treated with PMA and ionomycin for 24h.  Both WT1 splice variants could be 
expressed and any effects seen were therefore not the result of uneven expression (Fig.III.8C).  
In addition, the WT1-KTS is the variant which has transcription factor abilities, and the 
presence of WT1+KTS would therefore act as a control in the effects seen.  Specific apoptosis 
analysis of Jurkat cells treated as described above showed that WT1 greatly increased AICD 
(Fig.III.8B). This increase was attributed only to the WT1-KTS variant as the WT1+KTS had 
absolutely no effect.  Moreover, blockage of the WT1-KTS –mediated AICD with an 
antibody against the CD95L, reconfirming that the CD95/CD95L system was involved 
(Fig.III.8A).  This experiment indicates that WT1-KTS brings about apoptosis and is in 
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agreement with previous reports that support an apoptotic role for the WT1-KTS variant 
(Morrison et al, 2005; Murata et al, 1997). 
 
In the second system used in this direction, a WT1-expressing cell line with high AICD was 
chosen. In this setting, WT1 was silenced in CEM cells by siRNA.  The WT1 silencing 
oligonucleotide could reduce WT1 protein levels in a dose-dependent manner and itself had 
no effect on the apoptosis status of the cells (Fig.III.10A and III.9B).  After introducing the 
appropriate siRNA amounts to achieve maximum WT1 knock-down efficiency and 
stimulating the cells for 24h, but within the time-range of the knock-down effect, specific 
apoptosis was calculated.  Silencing of WT1 in CEM T cells not only brought down AICD 
levels in a dose-dependent manner, but even resulted in cell proliferation (Fig.III.10B).  This 
finding is in disagreement with reports showing growth inhibition of fresh human leukaemic 
cell and cell lines by a WT1-siRNA (Yamagami et al, 1996; Hubinger et al, 2001).  It must be 
taken into account that the effects seen in our work were only detectable after cell stimulation. 
These two systems described above provide evidence for the first time that WT1 mediates 
AICD in leukaemic T cells that express it. 
 
 
 
3. WT1 interferes with CD95L expression 
 
 
As mentioned above, WT1 expression in the leukaemic cell lines investigated coincided with 
higher apoptotic cell death, which could be blocked with an antibody against the CD95L.  
This suggests that the CD95/CD95L system is involved.  To elucidate the connection between 
WT1 expression and CD95/CD95L system-mediated AICD, the CD95 system had to be 
analyzed.  In this context, expression of CD95 and CD95L were analyzed by RT-PCR in all 
the cell lines, either without any treatment or 3h after stimulation with PMA and ionomycin, a 
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time point when the stimulation effects are clearly seen on the CD95L (Li-Weber et al, 1998). 
RT-PCR for the CD95L mRNA revealed that it was inducible in all the cell lines 
(Fig.III.11A).  To be more accurate, quantitative real-time PCR was also carried out, which 
confirmed that all cell lines were responsive to PMA and ionomycin treatment by 
upregulating the CD95L, but it was clear that the induction levels in WT1-non-expressing cell 
lines (e.g., 2-fold increase in Jurkat) were very low when compared to WT1-expressing cell 
lines (e.g., 5-fold increase in Hut78 and 4-fold increase in CEM) (Fig.III.11B).  This is the 
first time that CD95L expression is reported to coincide with WT1 expression. 
 
The CD95 was also analyzed.  Changes in CD95 levels would indicate that the WT1 effect on 
AICD was not due to CD95L changes alone.  In this direction, CD95 was analyzed at the 
transcriptional level by RT-PCR and quantitative real-time PCR (Fig.III.12A and B).  The 
RT-PCR analysis showed that the receptor was expressed in all the cell lines and at almost 
constant levels.  The quantitative analysis supported further the expression of the receptor in 
all the cell lines.  There were small changes seen in either upregulation or downregulation 
after stimulation with PMA and ionomycin, but these changes did not coincide with WT1 
expression.  Moreover, cell surface staining for the receptor provided further evidence that 
CD95 is unaffected by WT1 expression (Fig.III.12C).  CD95 expression on the surface was 
detected in all the cell lines.  Surprisingly, in agreement with the mRNA analysis, the receptor 
amounts present on the surface remained equally high and unaffected after stimulation.  
Collectively, the above data indicates for the first time that WT1 affects the CD95/CD95L 
system-mediated AICD by interfering with CD95L expression.   
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4. WT1 upregulates the CD95L at the transcriptional level 
 
 
To better understand the relationship between CD95L expression and WT1, both WT1 splice 
variants (WT1-KTS and WT1+KTS) were ectopically expressed in WT1-non-expressing 
Jurkat cells and the mRNA levels of CD95 and CD95L were analyzed by quantitative real-
time PCR.  The CD95 mRNA levels were almost unaffected by the presence of either splicing 
isoform.  The CD95L levels however, were notably affected by the presence of WT1-KTS.  
The WT1-KTS brought about a 9-fold increase in the CD95L mRNA levels, whereas the 
WT1+KTS had only a very small effect (Fig.III.13A).  Western blot analysis of the 
transfected cells confirmed that both variants were expressed at equal levels, so the effects 
seen were attributed to the actual function of WT1-KTS (Fig.III.13B). In accordance, 
silencing of WT1 in the WT1-expressing CEM cells (as described before) resulted in a 
decrease of the CD95L mRNA levels as seen by quantitative real-time PCR.  This drop in the 
CD95L mRNA levels was siRNA dose-dependent (Fig.III.14).  Therefore, WT1 expression in 
the panel of the leukaemic cell lines studied coincided with CD95L expression, the presence 
of WT1 upregulated the CD95L and the absence of WT1 resulted in a reduction of CD95L 
mRNA levels.  This is the first report that shows the CD95L being upregulated upon 
stimulation in the presence of WT1 expression.  This suggests that WT1 interferes with 
CD95L expression. 
 
WT1-KTS is known to be a transcription factor which belongs to the Egr family of 
transcription factors and shares DNA binding specificity with the Egr family member, Egr1.  
It has been shown that the CD95L is a target for Egr factors, having three putative Egr1 
binding sites on its promoter (Li-Weber et al, 1999; Rengarajan et al, 2000) (Fig.III.15).  
Therefore, the most putative way that WT1 could interfere with CD95L expression would be 
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by directly acting on the CD95L promoter.  The first step to investigate this was by examining 
the whole promoter of the CD95L.  A luciferase reporter construct driven by the CD95L 
promoter (-680 to +100) was introduced in Jurkat cells along with WT1-KTS or WT1+KTS.  
Both WT1 splice variants could activate the promoter at very low levels in non-stimulation 
conditions, with the WT1-KTS causing a slightly higher activity.  After stimulation with 
PMA and ionomycin the promoter activity was greatly enhanced by both variants.  The effect 
of the WT1-KTS variant which has a higher affinity for DNA binding (Haber et al, 1991) was 
more prominent as it resulted in an 11-fold increase in the luciferase activity when compared 
to the 7-fold increase caused by the WT1+KTS (Fig.III.16).  In addition, a mutant CD95L 
promoter luciferase reporter construct was introduced in Jurkat cells followed by the 
introduction of WT1-KTS or WT1+KTS.  The mutant CD95L promoter has been shown to 
inhibit binding of Egr factors (Li-Weber et al, 1999) but it would also inhibit binding of WT1 
if WT1 would act on the CD95L promoter through the Egr1 sites. Under non-stimulation 
conditions, none of the splice variants of WT1 had an effect.  After stimulation, both variants 
had very small and similar effects, and the luciferase activity of the mutant promoter was of 
levels similar to those produced from the wild-type promoter without the presence of WT1 
(Fig.III.16).  Although it has been shown that Egr factors are necessary for TCR-mediated 
CD95L expression and work co-operatively with NF-AT (Latinis et al, 1997; Li-Weber & 
Krammer, 2002), the above results suggest for the first time that WT1 is also important and 
that it functions through the Egr1 DNA binding sites found on the CD95L promoter. 
 
Furthermore, analysis of the individual putative Egr1 binding site of the CD95L promoter 
provided more evidence for the need of WT1-KTS.  In this system a luciferase reporter 
construct under the influence of a minimal promoter containing a triplicate of each Egr1 
binding site from the CD95L promoter (i.e., 3x-120, 3x-180 and 3x-680) was transfected in 
Jurkat leukaemic cells along with WT1-KTS or WT1+KTS expression plasmids (Fig.III.17).  
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The WT1-KTS splice variant could activate luciferase production from all Egr1 sites with 
highest activity detected at the -180 site (Fig.III.17A).  To validate the specificity of WT1 for 
the Egr1 target sequences, a luciferase reporter construct under the influence of a minimal 
promoter containing five copies of the Sp1 binding sequence was introduced in Jurkat cells 
with WT1-KTS or WT1+KTS plasmid constructs.  Not surprisingly, the effect of WT1-KTS 
was negligible on the Sp1 target sequences (Fig.III.17B).  Based on the same transfection 
system, the luciferase reporter construct under the influence of a minimal promoter containing 
a triplicate of each Egr1 binding site from the CD95L promoter was co-transfected in Jurkat 
cells with WT1-KTS or WT1+KTS.  In addition to the previous setting, the cells were 
stimulated with PMA and ionomycin.  Stimulation conditions would give a better idea of how 
WT1 behaves on the CD95L promoter upon T cell stimulation.  Like at the non-stimulation 
conditions, the presence of WT1-KTS resulted in higher luciferase activity than when absent 
from all constructs.  The activity of the promoter was much higher after simulation when 
compared to no-stimulation for all three sites, but the Egr1 binding sites at -120 and -180 
showed a higher induction (Fig.III.18).  These results strongly support the ability of WT1-
KTS to influence CD95L expression at the promoter level for the first time and once more 
points out the regulatory abilities of the WT1-KTS variant (Davies et al, 1998).   
 
 
 
5. WT1 binds on the CD95L promoter at -120 
 
The capability of WT1 to upregulate the CD95L at the promoter level was therefore shown.    
The proof of which Egr1 binding site(s) is important for WT1 binding was given by an 
electrophoretic mobility shift assay with recombinant WT1-KTS and WT1+KTS proteins.  
Only the WT1-KTS proteins were able to form a complex with the oligonucleotides 
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representing Egr1 binding sites, confirming once more the transcription factor function of this 
splice variant (Fig.III.19) and its higher affinity for DNA binding (Haber et al, 1991).  
Although the previous experiments indicated that both the -120 and -180 could strongly 
respond to WT1-KTS with the -180 site reacting better, the actual protein interaction 
experiment showed very strong binding only on the -120 site.  The high inducible activity of 
the -180 site could be the result of NF-AT and Egr factors, as it the -180 site is a strong 
composite NF-AT/Egr binding site (Li-Weber et al, 1999; Holtz-Heppelmann et al, 1998).  
The fact that the results from the experiment of the luciferase reporter containing the -120 
Egr1 binding site agreed with the ability of recombinant WT1-KTS to form a complex with 
oligonucleotides representing this site, suggests for the first time that WT1-KTS binds on the 
CD95L promoter with high affinity at -120 and with lower affinities at the -180 and -860 
sites. 
 
The use of the recombinant WT1 protein might not exactly represent what is taking place 
within the nucleus, as other factors e.g., Egr2 and 3 might compete with WT1-KTS for 
binding on the CD95L promoter.  For this reason, an electrophoretic mobility shift assay with 
nuclear extracts from CEM, which express WT1, was carried out (Fig.III.20).  At non-
induction conditions three complexes were formed which were unspecific DNA-protein 
interactions as it has been shown before (Li-Weber et al, 1999).  After stimulation the band 
patterns clearly changed, as the formation of two new complexes, with slower mobility, was 
visible.  The new bands disappeared completely after addition of the antibody against Egr1, 
showing that Egr1 was involved in these complexes and an antibody against it pulled out all 
the proteins participating in the complex.  This finding agrees with a previous report that 
suggested a co-operative binding of Egr1 and NF-AT at that site (Li-Weber et al, 1999).   
The antibody against WT1 reduced the intensity of the bands substantially, indicating that 
WT1 was also involved in these complexes.  The persistence of the complexes could either be 
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due to the weak effect of the antibody or more likely due to a co-operative binding of Egr1 
and WT1 on that site of the promoter, which would strengthen WT1 binding on the promoter.  
The latter case is supported by the finding that there is no WT1 binding-complex at non-
stimulation conditions, when Egr1 is also not bound.  The specificity of the antibodies and the 
efficiency of the system were controlled with the addition of an antibody against Sp1, which 
as expected did not have any effects on the formed complexes. Moreover, the reductions in 
band intensities were not due to unequal loading as this was checked with the constitutively 
expressed factor NF-Y and it showed that all samples contained the same amount of nuclear 
proteins.  Therefore, according to these results, it is shown that WT1 can bind directly on the 
CD95L promoter.   
 
Collectively, this data indicates that WT1 binds on the CD95L promoter with higher affinity 
for the -120 and acting in concert with Egr1, they upregulate the CD95L.  In the system under 
investigation, when WT1 is expressed in a leukaemic cell line, it can bind to the CD95L 
promoter after TCR stimulation and activate CD95L expression.  CD95L in turn can react 
with CD95 and the apoptosis pathway is initiated (Fig.IV.2). 
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Figure IV.2. WT1’s mode of action in leukaemic T cells. Upon TCR stimulation (1), the 
signals emanating lead to dephosphorylation of NF-AT (2).  Active NF-AT translocates into 
the nucleus where it upregulates Egr factors (3). Binding of NF-AT and Egr proteins on the 
CD95L promoter in the presence of WT1 (4) lead to increased expression of CD95L (5) 
which upon binding with CD95 (6) signals for apoptosis (7).  In WT1 expressing cells (A) 
CD95L overexpression by WT1 overcomes resistance to apoptosis and the cell can then 
commit suicide. In WT1-non-expressing cells, CD95L expression is lower, anti-apoptotic 
signals are stronger and cells are more resistant to apoptosis (B). 
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6. Future perspectives 
 
 
After establishing a trustworthy RT-PCR and protein analysis system for detecting full-length 
WT1, it is necessary to re-screen all leukaemic cell lines that were previously reported to 
overexpress WT1 by using only RT-PCR against its C-terminus (Inoue et al, 1996; 1997).  
This will be the only way to clearly identify the percentage of the leukaemias that actually 
express WT1.  In relation to this, the exact stages at which WT1 is expressed during 
haematopoiesis should be re-assessed to make sure when WT1 is needed. 
 
Once the stages of haematopoiesis that express WT1 are determined, then the role of WT1 in 
the CD95 system has to be analyzed.  It is possible that WT1 expression is not only needed 
for differentiation but that it is also required to upregulate the CD95L in mediating apoptosis 
when there is a system malfunctioning in the cell (carcinogenesis) or even in the case of a T 
cell being autoreactive (negative selection).  Interestingly, WT1 belongs to the Egr family, 
and Egr factors have been shown to be important during thymic selection (Shao et al, 1997; 
Basson et al, 2000). 
 
Moreover, WT1 and Egr1-3 are zinc-finger transcription factors which in many cases have 
common binding sites on the DNA and this is also the situation on the CD95L promoter. As 
shown in this piece of work, it would be of further interest to see what is happening in the 
absence of Egr proteins.  Therefore, the different Egr proteins can be silenced in for example 
CEM cells or in T cells at different stages of development and then the ability of WT1 to bind 
on the CD95L promoter can be checked.  In addition, as mentioned in section I.7, WT1 has 
been shown to interact with several other proteins.  Therefore, the possibility for Egr and 
WT1 interaction can be analyzed by immunoprecipitation experiments and the yeast-two-
hybrid system in combination with the usage of wild-type and mutant proteins. 
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Finally, not to neglect the complicated splicing patterns of WT1 (section I.5), it is worth 
checking for the presence of different splice variants in the leukaemic cell lines in which part 
of the WT1 transcript was identified by RT-PCR (e.g., Jurkat).  For this, a northern blot 
analysis would be more suitable.  In the case of a truncated protein being expressed in these 
cells then its role should be analyzed.  This system may help identify the function of WT1 
transcript variants more easily due to the absence of full-length WT1, which when present 
could interfere and mask the effect of the other splice variants.  It is also possible that an N-
terminally truncated/zinc-finger containing WT1 protein (e.g., in Molt4) could have a 
dominant negative effect, acting on the promoter of the CD95L and hence suppressing its 
expression.  This event would in turn repress CD95L-mediated apoptosis.  Such a situation 
has been described before for an N-terminally truncated WT1 protein which lacked the 
repressor domain and was reported to have oncogenic properties (Hossain et al, 2006). 
 
 
7. Summary  
 
The aim of this work was to analyze the expression patterns of WT1 in human T-cell 
leukaemias and its role in apoptosis, in an attempt to understand its connection with 
leukaemogenesis.  This work was based on the study of leukaemic T-cell lines, some of which 
were previously reported to overexpress WT1, as the knowledge of WT1’s complex 
behaviour in primary T-cell leukaemias was very limited and this would not have provided a 
good starting point.  The expression analysis showed that only two out of the eight cell lines 
tested expressed WT1.  Two cell lines (Jurkat and Molt4) previously suggested to overexpress 
WT1 by RT-PCR on the C-terminus of the transcript (Inoue et al, 1997) actually did not, as  
RT-PCR on the whole transcript and Western blot analysis did not detect full-length WT1 
transcript and protein respectively.  This argues against several reports which support WT1 
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overexpression in leukaemias by carrying out RT-PCR on parts of the transcript (Inoue et al, 
1994; Inoue et al, 1996; Inoue et al, 1997).  In addition, it points out the need for a more 
careful examination for the presence of both the whole transcript and protein by using an 
antibody against the N-terminus of WT1 protein, before jumping into such conclusions.  One 
of the problems that most researchers have to face when analyzing WT1 mRNA expression is 
its very high GC content (NCBI), which impedes amplification of the N-terminus.  This 
problem was also encountered in this piece of work but with a lot of screening, optimization 
and persistence reliable results were obtained. This also raises the question of how 
trustworthy WT1 expression can be for targeted immunotherapy (Oka et al, 2000; Gao et al, 
2000), highlighting the need for a more careful examination of WT1 expression.  
 
WT1 is not expressed in the majority of the leukaemic cell lines studied and in the two cell 
lines that express it (Hut78 and CEM) it is wild-type. So how can it be involved in 
leukaemogenesis? WT1 (like Egr proteins) is expressed during the early stages of 
haematopoiesis (Maurer et al, 1997), and its expression is usually connected with more 
immature leukaemias (Sekiya et al, 1994; Patmasiriwat et al, 1996). As in kidney 
development, it is most likely necessary for differentiation and important for apoptosis 
induction in the unlucky event of system malfunctioning. Thus, premature cessation of 
expression would leave the cells in a non-differentiated phenotype.  Accumulation of such 
undifferentiated cells would end up in leukaemogenesis, a situation similar to Wilms’ tumors 
which gives WT1 a tumor suppressor function.  On the contrary, if WT1 expression continues 
after the appropriate time point during haematopoiesis, then this would result in a proliferative 
advantage of these cells through upregulation of anti-apoptotic Bcl-2 (Mayo et al, 1998), 
again leading to leukaemogenesis. The latter case, gives WT1 an oncogenic character. 
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The second interesting finding in this work was that WT1 is involved in AICD by 
upregulating the CD95L in leukaemic cells.  Under normal circumstances mature resting T 
cells do not express WT1.  Also, T cells do not express WT1 when they are activated.  That 
shows that WT1 is not involved in CD95L transcriptional regulation of mature T cells.  Why 
does it then upregulate the CD95L in leukaemic cells?  This is presumably an attempt of the 
cell to sense that there is something wrong and it has to commit suicide. This idea is also 
supported by the finding that WT1 can mediate apoptosis by upregulating Bak (Morrison et 
al, 2005). WT1 expression being either a remnant of the oncogenic process or deliberate 
would aim in T cell death upon activation (Fig.IV.2).   
 
The findings that WT1 is not overexpressed in leukaemic T-cell lines and that it mediates 
AICD by upregulating the CD95L, support a tumor suppressor function of WT1 in T cell 
leukaemias. 
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Ab Antibody 
AICD Activation induced cell death 
AIDS Acquired immunodeficiency syndrome 
APS Ammonium peroxidisulfate 
AREG Amphiregulin 
ATP Adenosine tri-phosphate 
FCS Foetal calf serum 
CDH1 Cadherin-1 (E-Cadherin) 
c-FLIP Cellular FLICE-inhibitory protein 
cDNA Complementary desoxyribozonucleic acid 
CsA Cyclosporine A 
DAG Diacylglycerol 
DD Death domain 
DED Death effector domain 
DISC Death-inducing signalling complex 
DTT Dithiotreitol 
Egr Early growth response proteins 
EGFR Epidermal growth factor receptor 
ES Embryonic stem cell 
FADD Fas-Associated death domain protein 
FLICE FADD-like ICE 
Gas2 Growth arrest-specific 2 
GFP Green fluorescent protein 
h Hour 
HSC Haematopoietic stem cell 
IAP Inhibitor of apoptosis 
ICAD Inhibitor of CAD (Caspase-activated DNase) 
ICE Interleukin-1β converting enzyme 
IgG  Immunoglobulin of G class 
IκB Inhibitor of κB proteins 
IR Irradiation 
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IKK IκB-Kinase 
JNK c-Jun N-terminal kinase 
IRF Interferon regulatory factor 
kDa Kilodalton 
LcK Lymphocyte-specific protein tyrosine kinase 
MAPK Mitogen-activated protein kinase 
MEK MAPK/ERK Kinase 
mRNA Messenger ribonucleic acid 
min Minute 
NF-AT Nuclear factor of activated T cells 
NFκB Nuclear factor κB 
NPHS1 Nephrin  
PAGE Polyacrylamide gel electrophoresis 
PARP poly(adenosine diphosphate-ribose) polymerase 
PKC Protein kinase 
PKC-θ Protein kinase C-θ 
PCR Polymerase chain reaction 
PODX Podocalyxin 
Rb Retinoblastoma 
ROS Reactive oxygen species 
RT-PCR Reverse-transcriptase polymerase chain reaction 
SDS Sodium dodecyl sulphate 
sec Seconds 
TCR T cell receptor 
TEMED Tetramethyl-ethyl diamin 
TNF Tumor necrosis factor 
TRAIL TNF-related apoptosis-inducing ligand 
UV  Ultraviolet  
V Volt 
XIAP X-linked inhibitor of apoptosis protein 
ZAP-70 Zeta-chain (TCR) associated protein kinase 70kDa 
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